Isolation	O
and	O
analysis	O
of	O
a	O
T	B-cell_line
cell	I-cell_line
clone	I-cell_line
variant	I-cell_line
exhibiting	O
constitutively	O
phosphorylated	B-protein
Ser133	I-protein
cAMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
.	O

In	O
driving	O
T	O
cell	O
proliferation	O
,	O
IL-2	B-protein
stimulates	O
a	O
new	O
program	O
of	O
gene	O
expression	O
that	O
includes	O
proliferating	B-protein
cell	I-protein
nuclear	I-protein
antigen	I-protein
(	O
PCNA	B-protein
)	O
,	O
a	O
requisite	O
processivity	O
factor	O
for	O
DNA	B-protein
polymerase	I-protein
delta	I-protein
.	O

PCNA	B-protein
transcription	O
is	O
regulated	O
in	O
part	O
through	O
tandem	O
CRE	B-DNA
sequences	I-DNA
in	O
the	O
promoter	B-protein
and	I-protein
CRE	I-protein
binding	I-protein
proteins	I-protein
;	O
IL-2	B-protein
stimulates	O
CREB	O
phosphorylation	O
in	O
the	O
resting	B-cell_line
cloned	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
,	O
L2	B-cell_line
.	O

After	O
culturing	O
L2	B-cell_line
cells	I-cell_line
for	O
greater	O
than	O
91	O
days	O
,	O
we	O
consistently	O
isolate	O
a	O
stable	O
variant	O
that	O
exhibits	O
constitutive	O
CREB	O
phosphorylation	O
.	O

L2	B-cell_line
and	I-cell_line
L2	I-cell_line
variant	I-cell_line
cells	I-cell_line
were	O
tested	O
for	O
IL-2	B-protein
responsiveness	O
and	O
rapamycin	O
sensitivity	O
with	O
respect	O
to	O
specific	O
kinase	O
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O

In	O
L2	B-cell_line
cells	I-cell_line
,	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
inhibited	O
the	O
following	O
:	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O

In	O
L2	B-cell_line
variant	I-cell_line
cells	I-cell_line
,	O
CREB	B-protein
kinase	I-protein
activity	O
was	O
constitutively	O
high	O
;	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
blocked	O
PCNA	O
expression	O
and	O
proliferation	O
.	O

These	O
results	O
indicate	O
that	O
IL-2	B-protein
induces	O
a	O
rapamycin-sensitive	O
,	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
in	O
L2	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
phosphorylation	O
of	O
CREB	B-protein
alone	O
is	O
not	O
sufficient	O
to	O
drive	O
PCNA	B-protein
expression	O
and	O
L2	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B-protein
.	O

a	NULL
2	NULL
nozzles	NULL
per	NULL
well	NULL
enable	NULL
cell	NULL
Cha	NULL
Check	NULL
out	NULL
how	NULL
Laminar	NULL
Wash	NULL
l	NULL
washing	NULL
by	NULL
creating	NULL
a	NULL
laminar	NULL
I	NULL
“	NULL
CU	NULL
RIOX	NULL
Accelerating	NULL
Life	NULL
Sciences	NULL
systems	NULL
replace	NULL
centrifugation	NULL
completely	NULL
in	NULL
handling	NULL
cells	NULL
See	NULL
How	NULL
It	NULL
Works	NULL
Ap	NULL
Isolation	NULL
and	NULL
Analysis	NULL
of	NULL
a	NULL
T	NULL
Cell	NULL
Clone	NULL
Varialﬂg	NULL
D	NULL
Imnmunolo	NULL
gy	NULL
Exhibiting	NULL
Constitutively	NULL
Phosphorylated	NULL
Ser	NULL
cAMP	NULL
Response	NULL
Element-Binding	NULL
Protein	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
_	NULL
Stanley	NULL
M.	NULL
Belkowski	NULL
,	NULL
Charles	NULL
S.	NULL
Rubin	NULL
and	NULL
Michael	NULL
B.	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Prystowsky	NULL
J	NULL
Immunol	NULL
1998	NULL
;	NULL
161:659-665	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/2/659	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
64	NULL
articles	NULL
,	NULL
31	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/2/659.full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
Isolation	NULL
and	NULL
Analysis	NULL
of	NULL
a	NULL
T	NULL
Cell	NULL
Clone	NULL
Variant	NULL
Exhibiting	NULL
Constitutively	NULL
Phosphorylated	NULL
Ser'*	NULL
>	NULL
cAMP	NULL
Response	NULL
Element-Binding	NULL
Protein	NULL
Stanley	NULL
M.	NULL
Belkowski	NULL
,	NULL
*	NULL
Charles	NULL
S.	NULL
Rubin	NULL
,	NULL
'	NULL
and	NULL
Michael	NULL
B.	NULL
Prystowsky**	NULL
In	NULL
driving	NULL
T	NULL
cell	NULL
proliferation	NULL
,	NULL
IL-2	NULL
stimulates	NULL
a	NULL
new	NULL
program	NULL
of	NULL
gene	NULL
expression	NULL
that	NULL
includes	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
(	NULL
PCNA	NULL
)	NULL
,	NULL
a	NULL
requisite	NULL
processivity	NULL
factor	NULL
for	NULL
DNA	NULL
polymerase	NULL
6	NULL
.	NULL

PCNA	NULL
transcription	NULL
is	NULL
regulated	NULL
in	NULL
part	NULL
through	NULL
tandem	NULL
CRE	NULL
sequences	NULL
in	NULL
the	NULL
promoter	NULL
and	NULL
CRE	NULL
binding	NULL
proteins	NULL
;	NULL
IL-2	NULL
stimulates	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
the	NULL
resting	NULL
cloned	NULL
T	NULL
lymphocyte	NULL
,	NULL
L2	NULL
.	NULL

After	NULL
culturing	NULL
L2	NULL
cells	NULL
for	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
,	NULL
we	NULL
consistently	NULL
isolate	NULL
a	NULL
stable	NULL
variant	NULL
that	NULL
exhibits	NULL
constitutive	NULL
CREB	NULL
phosphorylation	NULL
.	NULL

L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
were	NULL
tested	NULL
for	NULL
IL-2	NULL
responsiveness	NULL
and	NULL
rapamycin	NULL
sensitivity	NULL
with	NULL
respect	NULL
to	NULL
specific	NULL
kinase	NULL
activity	NULL
,	NULL
PCNA	NULL
expression	NULL
and	NULL
proliferation	NULL
.	NULL

In	NULL
L2	NULL
cells	NULL
,	NULL
IL-2	NULL
stimulated	NULL
and	NULL
rapamycin	NULL
inhibited	NULL
the	NULL
following	NULL
:	NULL
cAMP-independent	NULL
CREB	NULL
kinase	NULL
activity	NULL
,	NULL
PCNA	NULL
expression	NULL
and	NULL
proliferation	NULL
.	NULL

In	NULL
L2	NULL
variant	NULL
cells	NULL
,	NULL
CREB	NULL
kinase	NULL
activity	NULL
was	NULL
constitutively	NULL
high	NULL
;	NULL
IL-2	NULL
stimulated	NULL
and	NULL
rapamycin	NULL
blocked	NULL
PCNA	NULL
expression	NULL
and	NULL
proliferation	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
IL-2	NULL
induces	NULL
a	NULL
rapamycin-sensitive	NULL
,	NULL
cAMP-independent	NULL
CREB	NULL
kinase	NULL
activity	NULL
in	NULL
L2	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
PCNA	NULL
expression	NULL
and	NULL
L2	NULL
cell	NULL
proliferation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-2	NULL
.	NULL

-	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1998	NULL
,	NULL
161	NULL
:	NULL
659-665.	NULL
he	NULL
macrolide	NULL
rapamycin	NULL
is	NULL
a	NULL
potent	NULL
immunosuppressant	NULL
that	NULL
inhibits	NULL
cytokine-dependent	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Rapamycin	NULL
exerts	NULL
its	NULL
antiproliferative	NULL
effect	NULL
by	NULL
binding	NULL
to	NULL
intracellular	NULL
receptors	NULL
generating	NULL
complexes	NULL
that	NULL
inhibit	NULL
progression	NULL
from	NULL
G1	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
in	NULL
IL-2-stimulated	NULL
T-lymphocytes	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
IL-2-induced	NULL
proliferation	NULL
by	NULL
rapamycin	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
selective	NULL
inhibition	NULL
of	NULL
protein	NULL
syn-thesis	NULL
,	NULL
including	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
Ag	NULL
(	NULL
PCNA	NULL
)	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

PCNA	NULL
is	NULL
an	NULL
auxiliary	NULL
protein	NULL
for	NULL
DNA	NULL
polymerase	NULL
delta	NULL
(	NULL
6-10	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
PCNA-specific	NULL
Abs	NULL
to	NULL
inhibit	NULL
inducible	NULL
DNA	NULL
synthesis	NULL
in	NULL
isolated	NULL
nuclei	NULL
(	NULL
11	NULL
)	NULL
and	NULL
of	NULL
PCNA	NULL
antisense	NULL
oligonucle-otides	NULL
to	NULL
inhibit	NULL
proliferation	NULL
of	NULL
BALB/c	NULL
3T3	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
documents	NULL
the	NULL
role	NULL
of	NULL
this	NULL
protein	NULL
in	NULL
DNA	NULL
replication	NULL
.	NULL

PCNA	NULL
transcription	NULL
is	NULL
increased	NULL
in	NULL
IL-2-stimulated	NULL
T	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
.	NULL

The	NULL
5	NULL
'	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
PCNA	NULL
gene	NULL
contains	NULL
tandem	NULL
cAMP	NULL
response	NULL
elements	NULL
(	NULL
CREs	NULL
)	NULL
and	NULL
an	NULL
E2F-like	NULL
site	NULL
that	NULL
are	NULL
critical	NULL
for	NULL
IL-2	NULL
induction	NULL
and	NULL
optimal	NULL
transcriptional	NULL
activity	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

These	NULL
CRE	NULL
elements	NULL
bind	NULL
CREB	NULL
and	NULL
ATF1	NULL
.	NULL

Furthermore	NULL
,	NULL
IL-2	NULL
stimulates	NULL
CREB	NULL
and	NULL
ATF1	NULL
phosphorylation	NULL
in	NULL
T	NULL
cells	NULL
during	NULL
G1	NULL
activation	NULL
;	NULL
the	NULL
ability	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
to	NULL
bind	NULL
to	NULL
CRE	NULL
elements	NULL
in	NULL
the	NULL
promoter	NULL
as	NULL
Departments	NULL
of	NULL
*Pathology	NULL
and	NULL
*Pharmacology	NULL
,	NULL
Albert	NULL
Einstein	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Bronx	NULL
,	NULL
NY	NULL
10461	NULL
Received	NULL
for	NULL
publication	NULL
December	NULL
8	NULL
,	NULL
1997	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
March	NULL
18	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grant	NULL
RO1	NULL
MH51327-02	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Michael	NULL
B.	NULL
Prystowsky	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Albert	NULL
Einstein	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
1300	NULL
Morris	NULL
Park	NULL
Av-enue	NULL
,	NULL
Bronx	NULL
,	NULL
NY	NULL
10461	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
prystows	NULL
@	NULL
accom.yu.edu	NULL
3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
PCNA	NULL
,	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
Ag	NULL
;	NULL
CRE	NULL
,	NULL
cAMP	NULL
response	NULL
element	NULL
;	NULL
CREB	NULL
,	NULL
CRE-binding	NULL
protein	NULL
;	NULL
CBP	NULL
,	NULL
CREB-binding	NULL
protein	NULL
;	NULL
ATF1	NULL
,	NULL
activating	NULL
transcription	NULL
factor-1	NULL
;	NULL
PKA	NULL
,	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
A	NULL
;	NULL
RSK2	NULL
,	NULL
ribosomal	NULL
S6	NULL
kinase-2	NULL
;	NULL
PKI	NULL
,	NULL
PK	NULL
A-specific	NULL
kinase	NULL
inhibitor	NULL
;	NULL
HRP	NULL
,	NULL
horseradish	NULL
perox-idase	NULL
;	NULL
FRAP	NULL
,	NULL
FKBP12-rapamycin-associated	NULL
protein	NULL
.	NULL

Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
measured	NULL
using	NULL
a	NULL
gel-shift	NULL
assay	NULL
follows	NULL
a	NULL
similar	NULL
time	NULL
course	NULL
as	NULL
CREB/ATF1	NULL
phosphorylation	NULL
(	NULL
16	NULL
)	NULL
.	NULL

CREs	NULL
located	NULL
in	NULL
the	NULL
control	NULL
region	NULL
of	NULL
genes	NULL
are	NULL
recognized	NULL
by	NULL
several	NULL
proteins	NULL
that	NULL
are	NULL
members	NULL
of	NULL
the	NULL
activating	NULL
transcription	NULL
factor	NULL
subfamily	NULL
,	NULL
including	NULL
CREB	NULL
,	NULL
ATF1	NULL
,	NULL
and	NULL
others	NULL
(	NULL
17-20	NULL
)	NULL
.	NULL

The	NULL
best	NULL
studied	NULL
CRE-binding	NULL
protein	NULL
is	NULL
a	NULL
~40-kDa	NULL
protein	NULL
termed	NULL
CREB	NULL
(	NULL
17	NULL
,	NULL
20	NULL
)	NULL
.	NULL

CREB	NULL
transcriptional	NULL
activity	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
at	NULL
Ser'*	NULL
``	NULL
by	NULL
cAMP-dependent	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
(	NULL
21-24	NULL
)	NULL
.	NULL

Other	NULL
kinases	NULL
,	NULL
including	NULL
Ca	NULL
``	NULL
*	NULL
/calmodulin	NULL
dependent	NULL
kinases	NULL
(	NULL
CAMK	NULL
)	NULL
(	NULL
25	NULL
)	NULL
,	NULL
a	NULL
Ras-dependent	NULL
kinase	NULL
(	NULL
26	NULL
)	NULL
,	NULL
p90®°*	NULL
(	NULL
27	NULL
)	NULL
,	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
RSK2	NULL
(	NULL
29	NULL
)	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
phosphorylate	NULL
CREB	NULL
at	NULL
Ser'*	NULL
?	NULL

in	NULL
response	NULL
to	NULL
neurotrophic	NULL
factors	NULL
and	NULL
Ca**	NULL
fluxes	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
by	NULL
PKA	NULL
or	NULL
cAMP-independent	NULL
kinases	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
(	NULL
30-33	NULL
)	NULL
.	NULL

Although	NULL
cAMP	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
many	NULL
genes	NULL
through	NULL
CREs	NULL
(	NULL
34	NULL
)	NULL
,	NULL
increased	NULL
levels	NULL
of	NULL
cAMP	NULL
inhibit	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
35	NULL
)	NULL
,	NULL
and	NULL
IL-2	NULL
does	NULL
not	NULL
increase	NULL
cellular	NULL
levels	NULL
of	NULL
cAMP	NULL
(	NULL
16	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
a	NULL
kinase	NULL
other	NULL
than	NULL
PKA	NULL
is	NULL
responsible	NULL
for	NULL
CREB	NULL
activation	NULL
in	NULL
IL-2-stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
compare	NULL
L2	NULL
cells	NULL
with	NULL
newly	NULL
evolved	NULL
L2	NULL
variant	NULL
cells	NULL
that	NULL
exhibit	NULL
constitutive	NULL
Ser'*	NULL
>	NULL
CREB	NULL
phosphorylation	NULL
.	NULL

In	NULL
parental	NULL
L2	NULL
cells	NULL
,	NULL
IL-2	NULL
induces	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
PKA	NULL
,	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
cAMP-independent	NULL
CREB	NULL
kinase	NULL
and	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
CREB	NULL
phosphorylation	NULL
,	NULL
all	NULL
of	NULL
which	NULL
are	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
.	NULL

In	NULL
L2	NULL
cells	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
IL-2	NULL
regulates	NULL
CREB	NULL
phosphorylation	NULL
through	NULL
a	NULL
cAMP-independent	NULL
,	NULL
rapamycin-sensitive	NULL
kinase	NULL
.	NULL

In	NULL
L2	NULL
variant	NULL
cells	NULL
,	NULL
1	NULL
)	NULL
basal	NULL
levels	NULL
of	NULL
PKA	NULL
,	NULL
CREB	NULL
kinase	NULL
activity	NULL
,	NULL
and	NULL
phosphorylated	NULL
CREB	NULL
are	NULL
high	NULL
and	NULL
2	NULL
)	NULL
PKA	NULL
levels	NULL
,	NULL
CREB	NULL
kinase	NULL
activity	NULL
,	NULL
and	NULL
CREB	NULL
phosphorylation	NULL
are	NULL
not	NULL
affected	NULL
by	NULL
IL-2	NULL
or	NULL
rapamycin	NULL
.	NULL

In	NULL
both	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
,	NULL
rapamycin	NULL
inhibits	NULL
IL-2-stimulated	NULL
PCNA	NULL
expression	NULL
and	NULL
cellular	NULL
proliferation	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
Ser'**	NULL
CREB	NULL
phosphorylation	NULL
and	NULL
CREB	NULL
kinase	NULL
activity	NULL
are	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
PCNA	NULL
expression	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
that	NULL
rapamycin	NULL
does	NULL
not	NULL
exert	NULL
0022-1767/98/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
660	NULL
PKA	NULL
AND	NULL
CREB	NULL
KINASE	NULL
ACTIVITY	NULL
IN	NULL
IL-2-STIMULATED	NULL
T	NULL
CELLS	NULL
2nd	NULL
Antibody	NULL
Alone	NULL
Untreated	NULL
81¥94	NULL
-	NULL
NuV	NULL
-	NULL
luV	NULL
FIGURE	NULL
1	NULL
.	NULL

IL-2-stimulated	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
L2	NULL
cells	NULL
.	NULL

L2	NULL
cells	NULL
were	NULL
rested	NULL
in	NULL
IL-2-free	NULL
medium	NULL
for	NULL
24	NULL
h	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
100	NULL
units	NULL
of	NULL
IL-2	NULL
or	NULL
100	NULL
units	NULL
of	NULL
IL-2	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

L2	NULL
cells	NULL
were	NULL
labeled	NULL
for	NULL
phosphorylated	NULL
CREB	NULL
(	NULL
PCREB	NULL
)	NULL
and	NULL
total	NULL
CREB	NULL
using	NULL
specific	NULL
polyclonal	NULL
Abs	NULL
and	NULL
a	NULL
second	NULL
Ab	NULL
(	NULL
HRP-conjugated	NULL
donkey	NULL
anti-rabbit	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

As	NULL
a	NULL
negative	NULL
control	NULL
,	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
only	NULL
the	NULL
donkey	NULL
anti-rabbit	NULL
Ab	NULL
to	NULL
detect	NULL
nonspecific	NULL
secondary	NULL
Ab	NULL
binding	NULL
.	NULL

its	NULL
inhibitory	NULL
effect	NULL
on	NULL
PCNA	NULL
expression	NULL
primarily	NULL
through	NULL
inhibition	NULL
of	NULL
CREB	NULL
activation	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
culture	NULL
The	NULL
murine	NULL
T	NULL
helper	NULL
lymphocyte	NULL
clone	NULL
,	NULL
L2	NULL
,	NULL
was	NULL
cultured	NULL
with	NULL
irradiated	NULL
allogeneic	NULL
spleen	NULL
cells	NULL
and	NULL
30	NULL
U/ml	NULL
of	NULL
IL-2	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
isolated	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
and	NULL
incubated	NULL
overnight	NULL
in	NULL
IL-2-free	NULL
medium	NULL
.	NULL

Resting	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
100	NULL
U/ml	NULL
of	NULL
IL-2	NULL
or	NULL
100	NULL
U/ml	NULL
IL-2	NULL
plus	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
(	NULL
Research	NULL
Biochemicals	NULL
International	NULL
,	NULL
Natick	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
Highly	NULL
purified	NULL
human	NULL
re-combinant	NULL
IL-2	NULL
from	NULL
Escherichia	NULL
coli	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
Chiron	NULL
(	NULL
Em-eryville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

During	NULL
the	NULL
last	NULL
2	NULL
years	NULL
,	NULL
L2	NULL
cells	NULL
spontaneously	NULL
converted	NULL
to	NULL
the	NULL
variant	NULL
phenotype	NULL
(	NULL
increased	NULL
basal	NULL
levels	NULL
of	NULL
PKA	NULL
protein	NULL
and	NULL
CREB	NULL
kinase	NULL
activity	NULL
)	NULL
five	NULL
times	NULL
.	NULL

Once	NULL
the	NULL
cells	NULL
have	NULL
undergone	NULL
the	NULL
transition	NULL
to	NULL
the	NULL
variant	NULL
phenotype	NULL
,	NULL
they	NULL
have	NULL
not	NULL
reverted	NULL
to	NULL
the	NULL
parental	NULL
phenotype	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
variant	NULL
state	NULL
,	NULL
having	NULL
constitutively	NULL
high	NULL
phospho-CREB	NULL
,	NULL
is	NULL
maintained	NULL
with	NULL
storage	NULL
in	NULL
liquid	NULL
nitrogen	NULL
.	NULL

L2	NULL
variants	NULL
were	NULL
studied	NULL
as	NULL
a	NULL
het-erogenous	NULL
population	NULL
.	NULL

Kinase	NULL
analysis	NULL
Cell	NULL
lysates	NULL
were	NULL
processed	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Schwartz	NULL
et	NULL
al	NULL
.	NULL

(	NULL
39	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
.	NULL

The	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
potassium	NULL
phosphate	NULL
,	NULL
pH	NULL
7.5	NULL
,	NULL
containing	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
2-ME	NULL
,	NULL
0.1	NULL
PMSF	NULL
,	NULL
and	NULL
200	NULL
nM	NULL
methyl	NULL
isobutyl	NULL
xanthene	NULL
)	NULL
at	NULL
0°C	NULL
.	NULL

After	NULL
2	NULL
min	NULL
,	NULL
magnesium	NULL
acetate	NULL
was	NULL
added	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.5	NULL
mM	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
disrupted	NULL
by	NULL
passage	NULL
through	NULL
a	NULL
26-gauge	NULL
needle	NULL
.	NULL

The	NULL
lysate	NULL
was	NULL
centrifuged	NULL
at	NULL
100,000	NULL
X	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
collected	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
until	NULL
further	NULL
analysis	NULL
.	NULL

Lysates	NULL
were	NULL
analyzed	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Roskowski	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
added	NULL
to	NULL
the	NULL
protein	NULL
kinase	NULL
reaction	NULL
mixture	NULL
:	NULL
50	NULL
mM	NULL
MOPS	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
10	NULL
mM	NULL
magnesium	NULL
chloride	NULL
,	NULL
0.25	NULL
mg/ml	NULL
BSA	NULL
,	NULL
100	NULL
M	NULL
acceptor	NULL
peptide	NULL
,	NULL
kemptide	NULL
(	NULL
LRRASLG	NULL
)	NULL
(	NULL
Bachem	NULL
,	NULL
King	NULL
of	NULL
Prussia	NULL
,	NULL
PA	NULL
)	NULL
(	NULL
41	NULL
)	NULL
or	NULL
crebtide	NULL
(	NULL
SRRPSYRK	NULL
)	NULL
,	NULL
100	NULL
uM	NULL
[	NULL
y-	NULL
>	NULL
P	NULL
]	NULL
ATP	NULL
,	NULL
and	NULL
,	NULL
when	NULL
indicated	NULL
,	NULL
10	NULL
uM	NULL
cAMP	NULL
,	NULL
5	NULL
uM	NULL
PKI	NULL
,	NULL
a	NULL
PKA	NULL
specific	NULL
inhibitor	NULL
(	NULL
42	NULL
)	NULL
,	NULL
and/or	NULL
20	NULL
ng/ml	NULL
rapamycin	NULL
.	NULL

To	NULL
terminate	NULL
the	NULL
reaction	NULL
,	NULL
25	NULL
pl	NULL
of	NULL
sample	NULL
was	NULL
spotted	NULL
onto	NULL
Whatman	NULL
P81	NULL
phosphocellulose	NULL
discs	NULL
(	NULL
Maidstone	NULL
,	NULL
U.K.	NULL
)	NULL
and	NULL
immersed	NULL
in	NULL
75	NULL
mM	NULL
phosphoric	NULL
acid	NULL
for	NULL
2	NULL
min	NULL
.	NULL

The	NULL
discs	NULL
were	NULL
washed	NULL
twice	NULL
more	NULL
in	NULL
phosphoric	NULL
acid	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
phosphate	NULL
available	NULL
for	NULL
transfer	NULL
,	NULL
25	NULL
ul	NULL
from	NULL
a	NULL
sample	NULL
without	NULL
kinase	NULL
was	NULL
spotted	NULL
onto	NULL
a	NULL
phosphocellulose	NULL
disc	NULL
and	NULL
left	NULL
unwashed	NULL
.	NULL

The	NULL
discs	NULL
were	NULL
placed	NULL
in	NULL
scintillation	NULL
mixture	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
radioactivity	NULL
was	NULL
assessed	NULL
using	NULL
a	NULL
Wallac	NULL
1410	NULL
scintillation	NULL
counter	NULL
.	NULL

The	NULL
dose	NULL
dependence	NULL
of	NULL
protein	NULL
lysate	NULL
on	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
for	NULL
kemptide	NULL
and	NULL
crebtide	NULL
at	NULL
1	NULL
to	NULL
13	NULL
pug	NULL
of	NULL
protein	NULL
lysate	NULL
at	NULL
a	NULL
constant	NULL
reaction	NULL
time	NULL
of	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

These	NULL
reactions	NULL
yielded	NULL
a	NULL
sigmoid	NULL
curve	NULL
for	NULL
each	NULL
substrate	NULL
with	NULL
2	NULL
to	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
lysate	NULL
defining	NULL
the	NULL
linear	NULL
portion	NULL
of	NULL
the	NULL
curve	NULL
.	NULL

The	NULL
assays	NULL
were	NULL
also	NULL
performed	NULL
with	NULL
a	NULL
constant	NULL
amount	NULL
of	NULL
protein	NULL
(	NULL
2.5	NULL
ug	NULL
)	NULL
for	NULL
reaction	NULL
times	NULL
of	NULL
2	NULL
to	NULL
15	NULL
min	NULL
.	NULL

These	NULL
reactions	NULL
yielded	NULL
a	NULL
linear	NULL
curve	NULL
for	NULL
each	NULL
substrate	NULL
.	NULL

Based	NULL
on	NULL
this	NULL
information	NULL
,	NULL
the	NULL
experiments	NULL
shown	NULL
in	NULL
this	NULL
paper	NULL
were	NULL
performed	NULL
using	NULL
2.5	NULL
to	NULL
5.0	NULL
ug	NULL
of	NULL
protein	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Immunostaining	NULL
Cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
.	NULL

Cells	NULL
for	NULL
immunostaining	NULL
were	NULL
prepared	NULL
by	NULL
cytocentrifugation	NULL
of	NULL
50,000	NULL
cells	NULL
per	NULL
slide	NULL
and	NULL
by	NULL
fixation	NULL
with	NULL
4	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

The	NULL
slides	NULL
were	NULL
incubated	NULL
with	NULL
0.2	NULL
%	NULL
Triton	NULL
X-100	NULL
for	NULL
15	NULL
min	NULL
to	NULL
permeabilize	NULL
the	NULL
cells	NULL
,	NULL
were	NULL
blocked	NULL
with	NULL
normal	NULL
goat	NULL
serum	NULL
for	NULL
20	NULL
min	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
rabbit	NULL
anti-P-CREB	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
(	NULL
1:500	NULL
)	NULL
or	NULL
rabbit	NULL
anti-CREB-1	NULL
Ab	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
(	NULL
1:500	NULL
)	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
the	NULL
slides	NULL
were	NULL
incubated	NULL
sequentially	NULL
with	NULL
a	NULL
biotinylated	NULL
goat	NULL
anti-rabbit	NULL
Ab	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
(	NULL
1:400	NULL
)	NULL
,	NULL
with	NULL
ABC	NULL
peroxidase	NULL
reagent	NULL
(	NULL
Pierce	NULL
)	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
with	NULL
3,3'-diaminobenzine	NULL
tetrahydrochlo-ride	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
as	NULL
a	NULL
peroxidase	NULL
substrate	NULL
that	NULL
forms	NULL
an	NULL
insoluble	NULL
reaction	NULL
product	NULL
.	NULL

Positive	NULL
staining	NULL
was	NULL
visualized	NULL
using	NULL
differential	NULL
interference	NULL
contrast	NULL
optics	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
Cells	NULL
were	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
washed	NULL
with	NULL
PBS	NULL
.	NULL

Lysis	NULL
buffer	NULL
(	NULL
0.05	NULL
M	NULL
HEPES	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.01	NULL
M	NULL
sodium	NULL
fluoride	NULL
,	NULL
10	NULL
mM	NULL
sodium	NULL
vanadate	NULL
,	NULL
25	NULL
mM	NULL
benzamidine	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotonin	NULL
,	NULL
30	NULL
mM	NULL
sodium	NULL
pyrophosphate	NULL
,	NULL
20	NULL
ug/ml	NULL
PMSF	NULL
,	NULL
and	NULL
1	NULL
pg/ml	NULL
leupeptin	NULL
)	NULL
was	NULL
added	NULL
to	NULL
cells	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
,	NULL
and	NULL
the	NULL
lysate	NULL
was	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Cell	NULL
lysates	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
Laemmli	NULL
gel	NULL
sample	NULL
buffer	NULL
,	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
,	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
and	NULL
electrotransferred	NULL
onto	NULL
Immobilon	NULL
P	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
blocked	NULL
with	NULL
PBS-5	NULL
%	NULL
milk	NULL
for	NULL
1	NULL
h	NULL
and	NULL
then	NULL
immunoblotted	NULL
with	NULL
anti-mouse	NULL
PCNA	NULL
Ab	NULL
(	NULL
Sigma	NULL
)	NULL
(	NULL
1:2000	NULL
)	NULL
or	NULL
anti-PCREB	NULL
(	NULL
UBI	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
(	NULL
1:2000	NULL
)	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
washed	NULL
in	NULL
PBS-tween	NULL
,	NULL
blocked	NULL
with	NULL
PBS-5	NULL
%	NULL
milk	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
goat	NULL
anti-mouse	NULL
horseradish	NULL
peroxidase	NULL
(	NULL
HRP	NULL
)	NULL
-conjugated	NULL
Ab	NULL
(	NULL
Sigma	NULL
)	NULL
(	NULL
1:10,000	NULL
)	NULL
.	NULL

The	NULL
immunoreactive	NULL
band	NULL
was	NULL
visualized	NULL
using	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
;	NULL
Am-ersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Cellular	NULL
proliferation	NULL
After	NULL
treatment	NULL
with	NULL
IL-2	NULL
and	NULL
rapamycin	NULL
,	NULL
as	NULL
described	NULL
above	NULL
,	NULL
L2	NULL
cells	NULL
were	NULL
plated	NULL
on	NULL
96-well	NULL
plates	NULL
using	NULL
150	NULL
gl	NULL
of	NULL
each	NULL
culture	NULL
(	NULL
1.5	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
and	NULL
were	NULL
pulsed	NULL
for	NULL
2	NULL
h	NULL
with	NULL
1	NULL
wCi	NULL
of	NULL
[	NULL
°HJthymidine/well	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
PHD	NULL
cell	NULL
harvester	NULL
(	NULL
Cambridge	NULL
Technology	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
filters	NULL
were	NULL
placed	NULL
in	NULL
scintillation	NULL
mixture	NULL
,	NULL
and	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
was	NULL
assessed	NULL
using	NULL
a	NULL
Wallac	NULL
1410	NULL
scintillation	NULL
counter	NULL
.	NULL

Results	NULL
IL-2-stimulated	NULL
CREB	NULL
phosphorylation	NULL
Resting	NULL
murine-cloned	NULL
T	NULL
cells	NULL
,	NULL
L2	NULL
cells	NULL
,	NULL
were	NULL
stimulated	NULL
with	NULL
IL-2	NULL
or	NULL
treated	NULL
with	NULL
both	NULL
IL-2	NULL
and	NULL
rapamycin	NULL
for	NULL
24	NULL
h.	NULL
When	NULL
total	NULL
immunoreactive	NULL
CREB	NULL
was	NULL
examined	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
both	NULL
the	NULL
parental	NULL
and	NULL
the	NULL
variant	NULL
L2	NULL
cells	NULL
contained	NULL
similar	NULL
amounts	NULL
of	NULL
CREB	NULL
localized	NULL
both	NULL
to	NULL
the	NULL
perinuclear	NULL
space	NULL
and	NULL
the	NULL
nucleus	NULL
for	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Untreated	NULL
661	NULL
2nd	NULL
Antibody	NULL
Al	NULL
one	NULL
+1L2	NULL
+1L2	NULL
+Rapamycin	NULL
x*	NULL
,	NULL
*¥¥	NULL
838494	NULL
-	NULL
UY	NULL
83	NULL
%	NULL
)	NULL
-	NULL
uy	NULL
FIGURE	NULL
2	NULL
.	NULL

IL-2-stimulated	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

L2	NULL
variant	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
then	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
100	NULL
U	NULL
of	NULL
IL-2	NULL
or	NULL
100	NULL
U	NULL
of	NULL
IL-2	NULL
with	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

L2	NULL
variant	NULL
cells	NULL
were	NULL
labeled	NULL
for	NULL
phosphorylated	NULL
CREB	NULL
and	NULL
total	NULL
CREB	NULL
using	NULL
specific	NULL
polyclonal	NULL
Abs	NULL
and	NULL
a	NULL
second	NULL
Ab	NULL
(	NULL
HRP-conjugated	NULL
donkey	NULL
anti-rabbit	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

As	NULL
a	NULL
negative	NULL
control	NULL
,	NULL
cells	NULL
were	NULL
labeled	NULL
with	NULL
only	NULL
the	NULL
donkey	NULL
anti-rabbit	NULL
Ab	NULL
to	NULL
detect	NULL
nonspecific	NULL
secondary	NULL
Ab	NULL
binding	NULL
.	NULL

all	NULL
conditions	NULL
consistent	NULL
with	NULL
our	NULL
previous	NULL
findings	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
examined	NULL
Ser'**	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
L2	NULL
cells	NULL
by	NULL
immunohis-tochemistry	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

In	NULL
an	NULL
experiment	NULL
representative	NULL
of	NULL
cells	NULL
passed	NULL
for	NULL
less	NULL
than	NULL
61	NULL
days	NULL
,	NULL
phosphorylated	NULL
CREB	NULL
was	NULL
present	NULL
in	NULL
nuclei	NULL
,	NULL
and	NULL
levels	NULL
of	NULL
phosphorylation	NULL
increased	NULL
following	NULL
IL-2	NULL
stimulation	NULL
.	NULL

IL-2-induced	NULL
CREB	NULL
phosphorylation	NULL
was	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
.	NULL

After	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
in	NULL
passage	NULL
,	NULL
variant	NULL
L2	NULL
cells	NULL
emerged	NULL
that	NULL
had	NULL
high	NULL
basal	NULL
levels	NULL
of	NULL
nuclear	NULL
Ser'*	NULL
>	NULL
-phosphorylated	NULL
CREB	NULL
,	NULL
with	NULL
no	NULL
increase	NULL
following	NULL
treatment	NULL
with	NULL
IL-2	NULL
and	NULL
no	NULL
decrease	NULL
following	NULL
treatment	NULL
with	NULL
rapamycin	NULL
(	NULL
Figs	NULL
.	NULL

2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
variant	NULL
cells	NULL
appears	NULL
to	NULL
be	NULL
reduced	NULL
when	NULL
compared	NULL
with	NULL
the	NULL
parent	NULL
cells	NULL
;	NULL
the	NULL
significance	NULL
of	NULL
this	NULL
observation	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Relationship	NULL
of	NULL
phosphorylated	NULL
CREB	NULL
to	NULL
PCNA	NULL
expression	NULL
Biochemical	NULL
and	NULL
molecular	NULL
consequences	NULL
of	NULL
IL-2	NULL
stimulation	NULL
and	NULL
rapamycin	NULL
inhibition	NULL
are	NULL
assessed	NULL
in	NULL
the	NULL
context	NULL
of	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

Previous	NULL
studies	NULL
suggested	NULL
that	NULL
CREB	NULL
activation	NULL
may	NULL
be	NULL
a	NULL
key	NULL
regulatory	NULL
step	NULL
in	NULL
IL-2-stimulated	NULL
PCNA	NULL
expression	NULL
O	NULL
_	NULL
IL2	NULL
R	NULL
L2	NULL
PCREB	NULL
L2	NULL
Variant	NULL
PCREB	NULL
-~	NULL
L2	NULL
PCNA	NULL
pe-	NULL
®	NULL
L2	NULL
Variant	NULL
-	NULL
yous	NULL
PCNA	NULL
FIGURE	NULL
3	NULL
.	NULL

-	NULL
Ser'*	NULL
``	NULL
CREB	NULL
phosphorylation	NULL
and	NULL
PCNA	NULL
expression	NULL
in	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
,	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
R	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Ten	NULL
micrograms	NULL
of	NULL
total	NULL
protein	NULL
were	NULL
separated	NULL
by	NULL
acrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
transferred	NULL
to	NULL
a	NULL
membrane	NULL
.	NULL

Blots	NULL
were	NULL
incubated	NULL
with	NULL
HRP-conjugated	NULL
anti-P-CREB	NULL
or	NULL
anti-PCNA	NULL
Ab	NULL
and	NULL
developed	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
)	NULL
.	NULL

and	NULL
T	NULL
cell	NULL
proliferation	NULL
(	NULL
14	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
late	NULL
passage	NULL
L2	NULL
variant	NULL
cells	NULL
contain	NULL
constitutively	NULL
high	NULL
levels	NULL
of	NULL
phosphorylated	NULL
Ser'**	NULL
CREB	NULL
,	NULL
resting	NULL
late	NULL
passage	NULL
variant	NULL
cells	NULL
were	NULL
examined	NULL
for	NULL
potential	NULL
increases	NULL
in	NULL
basal	NULL
PCNA	NULL
expression	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
IL-2	NULL
and	NULL
rapamycin	NULL
on	NULL
PCNA	NULL
expression	NULL
and	NULL
cellular	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

Resting	NULL
late	NULL
passage	NULL
variant	NULL
cells	NULL
had	NULL
low	NULL
levels	NULL
of	NULL
PCNA	NULL
similar	NULL
to	NULL
those	NULL
found	NULL
in	NULL
parental	NULL
L2	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
IL-2	NULL
induced	NULL
,	NULL
and	NULL
rapamycin	NULL
inhibited	NULL
,	NULL
both	NULL
PCNA	NULL
expression	NULL
and	NULL
cellular	NULL
proliferation	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
CREB	NULL
phosphorylation	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
these	NULL
processes	NULL
and	NULL
that	NULL
rapamycin	NULL
does	NULL
not	NULL
inhibit	NULL
PCNA	NULL
expression	NULL
primarily	NULL
through	NULL
inhibition	NULL
of	NULL
CREB	NULL
activation	NULL
.	NULL

IL-2-inducible	NULL
kinase	NULL
activity	NULL
To	NULL
determine	NULL
the	NULL
mechanism	NULL
responsible	NULL
for	NULL
IL-2-inducible	NULL
and	NULL
constitutive	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
,	NULL
we	NULL
assessed	NULL
kinase	NULL
activities	NULL
in	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

PKA	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
Ser	NULL
``	NULL
is	NULL
well	NULL
known	NULL
(	NULL
21-24	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
kinase	NULL
activity	NULL
using	NULL
kemptide	NULL
,	NULL
a	NULL
protein	NULL
kinase	NULL
A	NULL
specific	NULL
substrate	NULL
.	NULL

PKA	NULL
exists	NULL
as	NULL
an	NULL
inactive	NULL
holoenzyme	NULL
that	NULL
is	NULL
dissociated	NULL
into	NULL
an	NULL
active	NULL
form	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cAMP	NULL
.	NULL

Assays	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cAMP	NULL
reflect	NULL
total	NULL
kinase	NULL
levels	NULL
in	NULL
the	NULL
cell	NULL
,	NULL
and	NULL
assays	NULL
done	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cAMP	NULL
reflect	NULL
the	NULL
amount	NULL
of	NULL
kinase	NULL
activity	NULL
at	NULL
the	NULL
time	NULL
of	NULL
cell	NULL
lysis	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
kinase	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
a	NULL
percent	NULL
of	NULL
the	NULL
amount	NULL
of	NULL
activity	NULL
in	NULL
unstimulated	NULL
L2	NULL
or	NULL
L2	NULL
variant	NULL
cells	NULL
plus	NULL
cAMP	NULL
.	NULL

In	NULL
early	NULL
passage	NULL
L2	NULL
cells	NULL
,	NULL
total	NULL
PKA	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
The	NULL
effect	NULL
of	NULL
IL-2	NULL
and	NULL
rapamycin	NULL
treatment	NULL
on	NULL
proliferation	NULL
of	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
``	NULL
Thymidine	NULL
Incorporation	NULL
(	NULL
1000	NULL
cpm	NULL
)	NULL
Days	NULL
of	NULL
Expt	NULL
.	NULL

No	NULL
.	NULL

_	NULL
Passage	NULL
0	NULL
IL-2	NULL
R	NULL
Early	NULL
1	NULL
21	NULL
2	NULL
96	NULL
2	NULL
Passage	NULL
2	NULL
42	NULL
2	NULL
70	NULL
3	NULL
(	NULL
L2	NULL
)	NULL
3	NULL
63	NULL
5	NULL
59	NULL
4	NULL
Late	NULL
4	NULL
91	NULL
2	NULL
72	NULL
5	NULL
Passage	NULL
5	NULL
98	NULL
2	NULL
55	NULL
11	NULL
(	NULL
L2	NULL
variant	NULL
)	NULL
6	NULL
140	NULL
1	NULL
25	NULL
1	NULL
``	NULL
L2	NULL
cells	NULL
(	NULL
21-63	NULL
days	NULL
)	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
(	NULL
91-140	NULL
days	NULL
)	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
alone	NULL
for	NULL
24	NULL
h	NULL
(	NULL
IL-2	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
R	NULL
)	NULL
.	NULL

Proliferation	NULL
was	NULL
determined	NULL
by	NULL
uptake	NULL
of	NULL
*	NULL
[	NULL
H	NULL
}	NULL
thymidine	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
662	NULL
PKA	NULL
AND	NULL
CREB	NULL
KINASE	NULL
ACTIVITY	NULL
IN	NULL
IL-2-STIMULATED	NULL
T	NULL
CELLS	NULL
~	NULL
g	NULL
350	NULL
<	NULL
Kemptide	NULL
7	NULL
3004	NULL
ks	NULL
3	NULL
2	NULL
2504	NULL
O	NULL
5	NULL
2004	NULL
Si	NULL
2	NULL
,	NULL
1504	NULL
49	NULL
2	NULL
1004	NULL
40	NULL
4	NULL
a	NULL
-	NULL
201	NULL
n	NULL
n	NULL
w	NULL
&	NULL
ol	NULL
IIM	NULL
Ill	NULL
aon	NULL
fl	NULL
...	NULL
.-	NULL
Fob	NULL
rep	NULL
p	NULL
PPP	NULL
P	NULL
P	NULL
PPP	NULL
P	NULL
P	NULL
POP	NULL
POT	NULL
OPT	NULL
s	NULL
oyz	NULL
oss	NULL
oyz	NULL
oyz	NULL
oy®	NULL
ong	NULL
CS	NULL
CS	NULL
O	NULL
-~53	NULL
-§	NULL
0	NULL
-~S§	NULL
0	NULL
+CAMP	NULL
-	NULL
cAMP	NULL
+PKI	NULL
_	NULL
+cAMP	NULL
-	NULL
cAMP	NULL
+PKI	NULL
21-63	NULL
days	NULL
91-140	NULL
days	NULL
L2	NULL
L2	NULL
variant	NULL
FIGURE	NULL
4	NULL
.	NULL

Protein	NULL
kinase	NULL
A	NULL
activity	NULL
in	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
.	NULL

L2	NULL
cells	NULL
from	NULL
short	NULL
time	NULL
of	NULL
passage	NULL
(	NULL
21-63	NULL
days	NULL
)	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
(	NULL
91-140	NULL
days	NULL
)	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
,	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
!	NULL
)	NULL

alone	NULL
for	NULL
24	NULL
h	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
(	NULL
IL-2+R	NULL
)	NULL
.	NULL

Total	NULL
protein	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
cells	NULL
,	NULL
and	NULL
5.0	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
assayed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
phosphorylate	NULL
kemptide	NULL
(	NULL
LRRASLG	NULL
)	NULL
,	NULL
a	NULL
PKA-selective	NULL
substrate	NULL
.	NULL

Enzyme	NULL
assays	NULL
were	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+cAMP	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-cAMP	NULL
)	NULL
of	NULL
cAMP	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
.	NULL

Some	NULL
enzyme	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
M	NULL
PKI	NULL
,	NULL
a	NULL
PKA-specific	NULL
inhibitor	NULL
.	NULL

Samples	NULL
were	NULL
assayed	NULL
in	NULL
duplicate	NULL
,	NULL
and	NULL
an	NULL
average	NULL
of	NULL
three	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
of	NULL
0	NULL
h	NULL
+	NULL
cAMP	NULL
kinase	NULL
activity	NULL
,	NULL
which	NULL
for	NULL
the	NULL
three	NULL
experiments	NULL
was	NULL
84	NULL
,	NULL
94	NULL
,	NULL
and	NULL
562	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
for	NULL
L2	NULL
cells	NULL
and	NULL
301	NULL
,	NULL
711	NULL
,	NULL
and	NULL
826	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
for	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

increases	NULL
following	NULL
stimulation	NULL
with	NULL
IL-2	NULL
for	NULL
24	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

However	NULL
PKA	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
cAMP	NULL
reveals	NULL
that	NULL
only	NULL
27	NULL
%	NULL
of	NULL
the	NULL
total	NULL
kinase	NULL
is	NULL
active	NULL
in	NULL
resting	NULL
cells	NULL
.	NULL

Despite	NULL
the	NULL
substantial	NULL
increase	NULL
in	NULL
PKA	NULL
levels	NULL
in	NULL
IL-2-stimulated	NULL
cells	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
active	NULL
PKA	NULL
remains	NULL
unchanged	NULL
.	NULL

Rapamycin	NULL
treatment	NULL
inhibited	NULL
the	NULL
IL-2-induced	NULL
increase	NULL
in	NULL
PKA	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
levels	NULL
of	NULL
active	NULL
kinase	NULL
.	NULL

Inhibition	NULL
by	NULL
PKI	NULL
,	NULL
a	NULL
PKA-specific	NULL
kinase	NULL
inhibitor	NULL
,	NULL
indicates	NULL
that	NULL
the	NULL
majority	NULL
of	NULL
kinase	NULL
activity	NULL
measured	NULL
using	NULL
kemptide	NULL
can	NULL
be	NULL
attributed	NULL
to	NULL
PKA	NULL
.	NULL

In	NULL
the	NULL
L2	NULL
variant	NULL
,	NULL
passed	NULL
for	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
,	NULL
a	NULL
different	NULL
pattern	NULL
of	NULL
kinase	NULL
activity	NULL
was	NULL
seen	NULL
after	NULL
IL-2	NULL
stimulation	NULL
.	NULL

Instead	NULL
of	NULL
an	NULL
increase	NULL
in	NULL
PKA	NULL
levels	NULL
after	NULL
IL-2	NULL
treatment	NULL
,	NULL
a	NULL
decrease	NULL
was	NULL
observed	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
active	NULL
kinase	NULL
remained	NULL
low	NULL
at	NULL
33	NULL
%	NULL
and	NULL
decreased	NULL
after	NULL
IL-2	NULL
treatment	NULL
.	NULL

Rapamycin	NULL
treatment	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
total	NULL
or	NULL
active	NULL
PKA	NULL
levels	NULL
.	NULL

The	NULL
reaction	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PKI	NULL
again	NULL
revealed	NULL
that	NULL
most	NULL
of	NULL
the	NULL
kinase	NULL
activity	NULL
measured	NULL
was	NULL
PKA	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
kinases	NULL
that	NULL
phosphorylate	NULL
CREB	NULL
,	NULL
similar	NULL
experiments	NULL
were	NULL
performed	NULL
using	NULL
crebtide	NULL
as	NULL
a	NULL
substrate	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Crebtide	NULL
contains	NULL
the	NULL
Ser'*	NULL
``	NULL
phosphorylation	NULL
site	NULL
of	NULL
the	NULL
CREB	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
(	NULL
30-33	NULL
)	NULL
.	NULL

In	NULL
early	NULL
passage	NULL
L2	NULL
cells	NULL
,	NULL
IL-2	NULL
stimulation	NULL
resulted	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
CREB	NULL
kinase	NULL
activity	NULL
that	NULL
was	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
PKA	NULL
(	NULL
kemptide	NULL
substrate	NULL
)	NULL
,	NULL
most	NULL
of	NULL
this	NULL
kinase	NULL
activity	NULL
was	NULL
cAMP	NULL
independent	NULL
and	NULL
inhibited	NULL
to	NULL
a	NULL
much	NULL
lesser	NULL
extent	NULL
by	NULL
PKI	NULL
,	NULL
indicating	NULL
that	NULL
CREB	NULL
kinase	NULL
activity	NULL
is	NULL
not	NULL
PKA	NULL
.	NULL

In	NULL
L2	NULL
variant	NULL
cells	NULL
passed	NULL
for	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
,	NULL
IL-2	NULL
did	NULL
not	NULL
cause	NULL
an	NULL
increase	NULL
in	NULL
CREB	NULL
kinase	NULL
activity	NULL
.	NULL

The	NULL
kinase	NULL
activity	NULL
was	NULL
~	NULL
350	NULL
ps	NULL
TG	NULL
300	NULL
Crebtide	NULL
+	NULL
a	NULL
250	NULL
{	NULL
«	NULL
2	NULL
200	NULL
0	NULL
&	NULL
&	NULL
150	NULL
>	NULL
2	NULL
>	NULL
1001	NULL
Fut	NULL
U	NULL
<	NULL
-	NULL
504	NULL
I	NULL
]	NULL
f	NULL
[	NULL
C	NULL
o	NULL
ll	NULL
‘	NULL
lllllqug	NULL
s	NULL
00	NULL
ony	NULL
oop	NULL
cup	NULL
cop	NULL
cop	NULL
oof	NULL
_	NULL
-_	NULL
i	NULL
_	NULL
!	NULL

_	NULL
!	NULL

_	NULL
+CAMP	NULL
-	NULL
cAMP	NULL
+PKI	NULL
_	NULL
+cAMP	NULL
-cAMP	NULL
+PKI	NULL
21-63	NULL
days	NULL
91-140	NULL
days	NULL
L2	NULL
L2	NULL
variant	NULL
FIGURE	NULL
5	NULL
.	NULL

CREB	NULL
kinase	NULL
activity	NULL
in	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

L2	NULL
cells	NULL
from	NULL
short	NULL
time	NULL
of	NULL
passage	NULL
(	NULL
21-63	NULL
days	NULL
)	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
(	NULL
91-140	NULL
days	NULL
)	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
,	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
24	NULL
h	NULL
(	NULL
IL-2+R	NULL
)	NULL
.	NULL

Total	NULL
protein	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
cells	NULL
,	NULL
and	NULL
5.0	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
assayed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
phosphorylate	NULL
crebtide	NULL
(	NULL
SRRPSYRK	NULL
)	NULL
,	NULL
a	NULL
substrate	NULL
that	NULL
contains	NULL
the	NULL
Ser'*	NULL
phosphorylation	NULL
site	NULL
of	NULL
CREB	NULL
.	NULL

Enzyme	NULL
assays	NULL
were	NULL
done	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+cAMP	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-cAMP	NULL
)	NULL
of	NULL
cAMP	NULL
(	NULL
10	NULL
uM	NULL
)	NULL
.	NULL

Some	NULL
enzyme	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
uM	NULL
PKI	NULL
,	NULL
a	NULL
PKA-specific	NULL
inhibitor	NULL
.	NULL

Samples	NULL
were	NULL
assayed	NULL
in	NULL
duplicate	NULL
,	NULL
and	NULL
an	NULL
average	NULL
of	NULL
three	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
of	NULL
0	NULL
h	NULL
+	NULL
cAMP	NULL
kinase	NULL
activity	NULL
,	NULL
which	NULL
for	NULL
the	NULL
three	NULL
experiments	NULL
was	NULL
93	NULL
,	NULL
99	NULL
,	NULL
and	NULL
391	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
for	NULL
L2	NULL
cells	NULL
and	NULL
274	NULL
,	NULL
870	NULL
,	NULL
and	NULL
1206	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
for	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

cAMP	NULL
independent	NULL
,	NULL
and	NULL
there	NULL
was	NULL
a	NULL
greater	NULL
resistance	NULL
to	NULL
inhibition	NULL
with	NULL
PKI	NULL
than	NULL
that	NULL
seen	NULL
with	NULL
kemptide	NULL
as	NULL
a	NULL
substrate	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
L2	NULL
cells	NULL
,	NULL
rapamycin	NULL
had	NULL
no	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
kinase	NULL
activity	NULL
.	NULL

Effect	NULL
of	NULL
cell	NULL
aging	NULL
on	NULL
kinase	NULL
activity	NULL
The	NULL
inability	NULL
of	NULL
IL-2	NULL
to	NULL
induce	NULL
kinase	NULL
activity	NULL
in	NULL
older	NULL
cultures	NULL
appears	NULL
to	NULL
result	NULL
from	NULL
a	NULL
change	NULL
in	NULL
basal	NULL
kinase	NULL
activity	NULL
as	NULL
the	NULL
cultures	NULL
age	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

PKA	NULL
activity	NULL
in	NULL
cells	NULL
passed	NULL
for	NULL
less	NULL
than	NULL
63	NULL
days	NULL
was	NULL
at	NULL
an	NULL
average	NULL
of	NULL
250	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
and	NULL
was	NULL
inducible	NULL
to	NULL
an	NULL
average	NULL
of	NULL
640	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
.	NULL

Cells	NULL
that	NULL
were	NULL
passed	NULL
for	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
had	NULL
an	NULL
average	NULL
resting	NULL
PKA	NULL
level	NULL
of	NULL
610	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
and	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
.	NULL

When	NULL
crebtide	NULL
was	NULL
used	NULL
as	NULL
the	NULL
substrate	NULL
,	NULL
resting	NULL
kinase	NULL
activity	NULL
in	NULL
cells	NULL
passed	NULL
for	NULL
fewer	NULL
than	NULL
63	NULL
days	NULL
was	NULL
at	NULL
an	NULL
average	NULL
of	NULL
90	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
and	NULL
was	NULL
inducible	NULL
to	NULL
an	NULL
average	NULL
value	NULL
of	NULL
500	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
.	NULL

The	NULL
average	NULL
resting	NULL
kinase	NULL
activity	NULL
of	NULL
cells	NULL
that	NULL
were	NULL
passed	NULL
for	NULL
greater	NULL
than	NULL
91	NULL
days	NULL
was	NULL
780	NULL
pmol	NULL
phosphate	NULL
transferred/min/mg	NULL
protein	NULL
and	NULL
also	NULL
could	NULL
not	NULL
be	NULL
induced	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
aged	NULL
cultures	NULL
,	NULL
basal	NULL
kinase	NULL
activity	NULL
for	NULL
each	NULL
substrate	NULL
was	NULL
equal	NULL
to	NULL
or	NULL
greater	NULL
than	NULL
the	NULL
induced	NULL
levels	NULL
in	NULL
younger	NULL
cultures	NULL
.	NULL

Rapamycin	NULL
effect	NULL
on	NULL
kinase	NULL
activity	NULL
in	NULL
vitro	NULL
To	NULL
determine	NULL
whether	NULL
rapamycin	NULL
has	NULL
a	NULL
direct	NULL
effect	NULL
on	NULL
the	NULL
kinases	NULL
studied	NULL
,	NULL
kinase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

PKA	NULL
and	NULL
CREB	NULL
kinase	NULL
activities	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
rapamycin	NULL
.	NULL

This	NULL
implies	NULL
that	NULL
rapamycin	NULL
exerts	NULL
its	NULL
inhibitory	NULL
effect	NULL
on	NULL
the	NULL
increase	NULL
in	NULL
kinase	NULL
levels	NULL
or	NULL
kinase	NULL
activation	NULL
but	NULL
not	NULL
directly	NULL
on	NULL
kinase	NULL
activity	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
a	NULL
m	NULL
E	NULL
't	NULL
2000	NULL
3	NULL
~	NULL
o	NULL
]	NULL
£	NULL
1500	NULL
4	NULL
a.	NULL
fur	NULL
UC	NULL
©	NULL
=	NULL
1000	NULL
4	NULL
o	NULL
he	NULL
w	NULL
<	NULL
fi	NULL
2	NULL
500	NULL
4	NULL
R	NULL
E	NULL
]	NULL
but	NULL
€	NULL
5	NULL
-	NULL
o	NULL
{	NULL
4	NULL
MHL	NULL
2	NULL
+o	NULL
+o	NULL
o	NULL
+o+	NULL
Kemptide	NULL
a	NULL
.	NULL

+	NULL
+	NULL
+	NULL
+	NULL
Crebtide	NULL
0	NULL
24	NULL
0	NULL
24	NULL
0	NULL
24	NULL
0	NULL
24	NULL
Time	NULL
<	NULL
63	NULL
>	NULL
91	NULL
<	NULL
63	NULL
91	NULL
Days	NULL
in	NULL
passage	NULL
L2	NULL
L2	NULL
L2	NULL
L2	NULL
variant	NULL
variant	NULL
FIGURE	NULL
6	NULL
.	NULL

-	NULL
Basal	NULL
kinase	NULL
levels	NULL
are	NULL
elevated	NULL
in	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

L2	NULL
cells	NULL
from	NULL
short	NULL
time	NULL
of	NULL
passage	NULL
(	NULL
21-63	NULL
days	NULL
)	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
(	NULL
91-140	NULL
days	NULL
)	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Total	NULL
protein	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
cells	NULL
,	NULL
and	NULL
5.0	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
assayed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
phosphorylate	NULL
kemptide	NULL
(	NULL
LRRASLG	NULL
)	NULL
,	NULL
a	NULL
PKA-selective	NULL
substrate	NULL
,	NULL
or	NULL
crebtide	NULL
(	NULL
SRRPSYRK	NULL
)	NULL
,	NULL
a	NULL
substrate	NULL
that	NULL
contains	NULL
the	NULL
Ser'**	NULL
phosphorylation	NULL
site	NULL
of	NULL
CREB	NULL
.	NULL

Samples	NULL
were	NULL
assayed	NULL
in	NULL
duplicate	NULL
,	NULL
and	NULL
an	NULL
average	NULL
of	NULL
three	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
picomole	NULL
of	NULL
phosphate	NULL
transferred	NULL
in	NULL
a	NULL
10-min	NULL
reaction	NULL
.	NULL

Protein	NULL
(	NULL
2.5-5.0	NULL
pug	NULL
)	NULL
was	NULL
used	NULL
for	NULL
each	NULL
reaction	NULL
.	NULL

Discussion	NULL
Stimulation	NULL
of	NULL
the	NULL
murine-cloned	NULL
T	NULL
lymphocyte	NULL
L2	NULL
with	NULL
IL-2	NULL
drives	NULL
entry	NULL
and	NULL
progression	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
36	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Increased	NULL
PCNA	NULL
expression	NULL
has	NULL
been	NULL
shown	NULL
in	NULL
IL-2-stimulated	NULL
T	NULL
cells	NULL
(	NULL
13	NULL
)	NULL
;	NULL
there	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
close	NULL
temporal	NULL
link	NULL
with	NULL
the	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
protein	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
proteins	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
PCNA	NULL
CRE	NULL
sequences	NULL
(	NULL
14	NULL
,	NULL
16	NULL
)	NULL
.	NULL

CRE	NULL
sequences	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
promoter	NULL
activity	NULL
,	NULL
and	NULL
rapamycin	NULL
inhibits	NULL
IL-2-stimulated	NULL
CREB	NULL
binding	NULL
to	NULL
these	NULL
elements	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
discovery	NULL
of	NULL
an	NULL
L2	NULL
cell	NULL
variant	NULL
that	NULL
has	NULL
constitutively	NULL
phosphorylated	NULL
CREB	NULL
allowed	NULL
us	NULL
to	NULL
test	NULL
the	NULL
hypothesis	NULL
that	NULL
CREB	NULL
activation	NULL
is	NULL
a	NULL
key	NULL
rapamycin-sensitive	NULL
step	NULL
in	NULL
IL-2-stimulated	NULL
PCNA	NULL
expression	NULL
and	NULL
proliferation	NULL
.	NULL

Phosphorylation	NULL
of	NULL
the	NULL
Ser'*	NULL
>	NULL
residue	NULL
on	NULL
CREB	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
have	NULL
great	NULL
importance	NULL
in	NULL
gene	NULL
expression	NULL
and	NULL
proliferation	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
inability	NULL
of	NULL
T	NULL
cells	NULL
expressing	NULL
the	NULL
dominate-negative	NULL
form	NULL
of	NULL
CREB	NULL
to	NULL
produce	NULL
IL-2	NULL
and	NULL
undergo	NULL
cell	NULL
cycle	NULL
progression	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
binding	NULL
of	NULL
the	NULL
protein	NULL
to	NULL
CRE	NULL
sites	NULL
(	NULL
21	NULL
,	NULL
23	NULL
,	NULL
26	NULL
,	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Maximal	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
PCNA	NULL
promoter	NULL
requires	NULL
CREB/	NULL
ATF1	NULL
transcription	NULL
factors	NULL
following	NULL
IL-2	NULL
stimulation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Previous	NULL
data	NULL
generated	NULL
using	NULL
the	NULL
L2	NULL
cell	NULL
line	NULL
have	NULL
shown	NULL
an	NULL
increase	NULL
in	NULL
PCNA	NULL
expression	NULL
after	NULL
IL-2	NULL
stimulation	NULL
and	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
rapamycin	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Despite	NULL
the	NULL
high	NULL
constitutive	NULL
kinase	NULL
activity	NULL
and	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
variant	NULL
cells	NULL
,	NULL
PCNA	NULL
expression	NULL
was	NULL
low	NULL
in	NULL
untreated	NULL
and	NULL
rapamycin-treated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CREB	NULL
activation	NULL
alone	NULL
is	NULL
insufficient	NULL
for	NULL
PCNA	NULL
gene	NULL
expression	NULL
.	NULL

CREB	NULL
transcriptional	NULL
activation	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
require	NULL
other	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
example	NULL
,	NULL
CD28	NULL
signaling	NULL
was	NULL
required	NULL
for	NULL
full	NULL
transcriptional	NULL
activity	NULL
of	NULL
CREB	NULL
in	NULL
ELA	NULL
cells	NULL
,	NULL
whereas	NULL
Ser'**	NULL
phospho-CREB	NULL
alone	NULL
was	NULL
insufficient	NULL
for	NULL
CRE-CAT	NULL
(	NULL
chloram-phenicol	NULL
acetyltransferase	NULL
)	NULL
gene	NULL
expression	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Similarly	NULL
in	NULL
Ju-	NULL
663	NULL
700	NULL
600	NULL
4	NULL
5004	NULL
400	NULL
4	NULL
300	NULL
{	NULL
2004	NULL
100	NULL
Phosphate	NULL
Transferred	NULL
(	NULL
pmol	NULL
/min/mg	NULL
)	NULL
0	NULL
_-	NULL
--	NULL
--	NULL
-=*	NULL
--	NULL
4	NULL
Rap	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
0	NULL
hour	NULL
24	NULL
hour	NULL
0	NULL
hour	NULL
24	NULL
hour	NULL
Kemptide	NULL
Crebtide	NULL
FIGURE	NULL
7	NULL
.	NULL

-	NULL
Rapamycin	NULL
does	NULL
not	NULL
inhibit	NULL
kinase	NULL
activity	NULL
in	NULL
vitro	NULL
.	NULL

L2	NULL
cells	NULL
were	NULL
rested	NULL
for	NULL
24	NULL
h	NULL
in	NULL
IL-2-free	NULL
medium	NULL
and	NULL
left	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
IL-2	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
for	NULL
24	NULL
h	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Total	NULL
protein	NULL
was	NULL
extracted	NULL
from	NULL
the	NULL
cells	NULL
,	NULL
and	NULL
5.0	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
assayed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
phosphorylate	NULL
kemptide	NULL
(	NULL
LRRASLG	NULL
)	NULL
,	NULL
a	NULL
PKA-selective	NULL
substrate	NULL
,	NULL
or	NULL
crebtide	NULL
(	NULL
SRRPSYRK	NULL
)	NULL
,	NULL
a	NULL
substrate	NULL
that	NULL
contains	NULL
the	NULL
Ser'**	NULL
phosphorylation	NULL
site	NULL
of	NULL
CREB	NULL
.	NULL

Untreated	NULL
and	NULL
24-h	NULL
IL-2-stimulated	NULL
L2	NULL
cells	NULL
were	NULL
assayed	NULL
for	NULL
kinase	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
rapamycin	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL

1	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
picomole	NULL
of	NULL
phosphate	NULL
transferred	NULL
in	NULL
a	NULL
10-min	NULL
reaction	NULL
.	NULL

Protein	NULL
(	NULL
2.5-5.0	NULL
ug	NULL
)	NULL
was	NULL
used	NULL
for	NULL
each	NULL
reaction	NULL
.	NULL

rkat	NULL
cells	NULL
CREB	NULL
phosphorylation	NULL
alone	NULL
was	NULL
insufficient	NULL
for	NULL
transcriptional	NULL
regulation	NULL
;	NULL
PKA-mediated	NULL
phosphorylation	NULL
of	NULL
the	NULL
CREB	NULL
binding	NULL
protein	NULL
(	NULL
CBP	NULL
)	NULL
was	NULL
required	NULL
.	NULL

(	NULL
48	NULL
)	NULL
.	NULL

CBP	NULL
phosphorylation	NULL
allows	NULL
a	NULL
complex	NULL
to	NULL
be	NULL
formed	NULL
with	NULL
phospho-CREB	NULL
,	NULL
which	NULL
then	NULL
binds	NULL
to	NULL
the	NULL
CRE	NULL
.	NULL

Therefore	NULL
,	NULL
a	NULL
similar	NULL
form	NULL
of	NULL
control	NULL
may	NULL
be	NULL
active	NULL
in	NULL
both	NULL
L2	NULL
cells	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
where	NULL
a	NULL
secondary	NULL
IL-2-mediated	NULL
phosphorylation	NULL
event	NULL
is	NULL
required	NULL
for	NULL
PCNA	NULL
transcription	NULL
.	NULL

While	NULL
the	NULL
variant	NULL
phenotype	NULL
showed	NULL
that	NULL
CREB	NULL
phosphorylation	NULL
alone	NULL
was	NULL
insufficient	NULL
for	NULL
PCNA	NULL
expression	NULL
,	NULL
there	NULL
is	NULL
strong	NULL
evidence	NULL
for	NULL
an	NULL
IL-2-inducible	NULL
,	NULL
rapamycin-sensitive	NULL
kinase	NULL
responsible	NULL
for	NULL
CREB	NULL
activation	NULL
that	NULL
is	NULL
required	NULL
for	NULL
optimal	NULL
PCNA	NULL
promoter	NULL
activity	NULL
(	NULL
14	NULL
)	NULL
.	NULL

cAMP-dependent	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
was	NULL
the	NULL
first	NULL
enzyme	NULL
identified	NULL
to	NULL
phosphorylate	NULL
CREB	NULL
at	NULL
Ser'*	NULL
>	NULL
(	NULL
21-24	NULL
)	NULL
.	NULL

Increased	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
occur	NULL
following	NULL
mito-genic	NULL
stimulation	NULL
of	NULL
splenic	NULL
B	NULL
lymphocytes	NULL
and	NULL
T	NULL
lymphocytes	NULL
(	NULL
49	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Elevation	NULL
of	NULL
cAMP	NULL
induces	NULL
the	NULL
translocation	NULL
of	NULL
PKA	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
51	NULL
)	NULL
.	NULL

While	NULL
this	NULL
information	NULL
suggests	NULL
that	NULL
IL-2-stim-ulation	NULL
may	NULL
act	NULL
in	NULL
part	NULL
through	NULL
PKA	NULL
activation	NULL
,	NULL
other	NULL
data	NULL
argue	NULL
against	NULL
the	NULL
role	NULL
of	NULL
PKA	NULL
in	NULL
CREB	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
example	NULL
,	NULL
IL-2	NULL
does	NULL
not	NULL
induce	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
levels	NULL
of	NULL
cAMP	NULL
during	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
L2	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
,	NULL
and	NULL
T	NULL
cell	NULL
proliferation	NULL
is	NULL
inhibited	NULL
by	NULL
high	NULL
cAMP	NULL
levels	NULL
(	NULL
35	NULL
,	NULL
52	NULL
)	NULL
,	NULL
potentially	NULL
through	NULL
cAMP-blocking	NULL
Raf-1	NULL
kinase	NULL
(	NULL
53	NULL
)	NULL
.	NULL

These	NULL
conflicting	NULL
data	NULL
create	NULL
a	NULL
paradox	NULL
;	NULL
two	NULL
possible	NULL
explanations	NULL
include	NULL
1	NULL
)	NULL
a	NULL
transient	NULL
activation	NULL
of	NULL
PKA	NULL
that	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
data	NULL
,	NULL
which	NULL
show	NULL
that	NULL
there	NULL
must	NULL
be	NULL
a	NULL
rise	NULL
followed	NULL
by	NULL
a	NULL
decrease	NULL
in	NULL
cAMP	NULL
levels	NULL
for	NULL
progression	NULL
of	NULL
T	NULL
cells	NULL
into	NULL
S	NULL
phase	NULL
(	NULL
50	NULL
)	NULL
,	NULL
or	NULL
2	NULL
)	NULL
a	NULL
kinase	NULL
other	NULL
than	NULL
PKA	NULL
activates	NULL
CREB	NULL
in	NULL
IL-2-stimulated	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
paradox	NULL
led	NULL
us	NULL
to	NULL
examine	NULL
PKA	NULL
levels	NULL
in	NULL
L2	NULL
and	NULL
L2	NULL
variant	NULL
cells	NULL
.	NULL

The	NULL
kinase	NULL
activity	NULL
responsible	NULL
for	NULL
kemptide	NULL
phosphorylation	NULL
is	NULL
PKA	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
dependence	NULL
on	NULL
cAMP	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
and	NULL
by	NULL
the	NULL
sensitivity	NULL
of	NULL
kinase	NULL
activity	NULL
to	NULL
the	NULL
inhibitor	NULL
peptide	NULL
,	NULL
PKI	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Since	NULL
PKA	NULL
activity	NULL
was	NULL
low	NULL
and	NULL
uninducible	NULL
by	NULL
IL-2	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
664	NULL
PKA	NULL
AND	NULL
CREB	NULL
KINASE	NULL
ACTIVITY	NULL
IN	NULL
IL-2-STIMULATED	NULL
T	NULL
CELLS	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
another	NULL
kinase	NULL
may	NULL
be	NULL
phosphorylating	NULL
CREB	NULL
in	NULL
IL-2-stimulated	NULL
cells	NULL
.	NULL

To	NULL
determine	NULL
other	NULL
possible	NULL
kinase	NULL
activ-ities	NULL
,	NULL
the	NULL
substrate	NULL
crebtide	NULL
was	NULL
used	NULL
in	NULL
the	NULL
kinase	NULL
assays	NULL
.	NULL

Crebtide	NULL
is	NULL
a	NULL
9-amino	NULL
acid	NULL
peptide	NULL
(	NULL
SRRPSYRK	NULL
)	NULL
containing	NULL
the	NULL
Ser'*	NULL
>	NULL
phosphorylation	NULL
site	NULL
shown	NULL
to	NULL
be	NULL
important	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CREB	NULL
interactions	NULL
with	NULL
DNA	NULL
and	NULL
other	NULL
regulatory	NULL
proteins	NULL
(	NULL
21-24	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
crebtide	NULL
reflects	NULL
phosphorylation	NULL
of	NULL
endogenous	NULL
CREB	NULL
protein	NULL
(	NULL
56	NULL
)	NULL
.	NULL

When	NULL
using	NULL
crebtide	NULL
as	NULL
the	NULL
substrate	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
cAMP-independent	NULL
,	NULL
IL-2-inducible	NULL
,	NULL
rapamycin-sensitive	NULL
kinase	NULL
was	NULL
shown	NULL
in	NULL
the	NULL
parental	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
almost	NULL
100	NULL
%	NULL
of	NULL
the	NULL
CREB	NULL
kinase	NULL
was	NULL
active	NULL
(	NULL
-cAMP	NULL
)	NULL
on	NULL
the	NULL
crebtide	NULL
substrate	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
while	NULL
only	NULL
about	NULL
25	NULL
%	NULL
of	NULL
the	NULL
PKA	NULL
kinase	NULL
was	NULL
active	NULL
(	NULL
-cAMP	NULL
)	NULL
on	NULL
the	NULL
kemptide	NULL
substrate	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

This	NULL
kinase	NULL
was	NULL
relatively	NULL
resistant	NULL
to	NULL
the	NULL
PKA	NULL
inhibitor	NULL
,	NULL
PKI	NULL
,	NULL
further	NULL
supporting	NULL
the	NULL
notion	NULL
that	NULL
it	NULL
is	NULL
not	NULL
PKA	NULL
.	NULL

Kinases	NULL
other	NULL
than	NULL
PKA	NULL
can	NULL
mediate	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
or	NULL
the	NULL
corresponding	NULL
Ser	NULL
residue	NULL
on	NULL
CRE	NULL
modulator	NULL
(	NULL
CREM	NULL
)	NULL
,	NULL
such	NULL
as	NULL
p90®°*	NULL
(	NULL
27	NULL
)	NULL
,	NULL
RSK2	NULL
(	NULL
29	NULL
)	NULL
,	NULL
Ca*	NULL
*	NULL
/calmodulin	NULL
kinase	NULL
II	NULL
(	NULL
26	NULL
,	NULL
57	NULL
)	NULL
,	NULL
a	NULL
Ras-dependent	NULL
protein	NULL
kinase	NULL
(	NULL
25	NULL
)	NULL
,	NULL
PKC	NULL
(	NULL
58	NULL
,	NULL
59	NULL
)	NULL
,	NULL
and	NULL
p70®®	NULL
kinase	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Of	NULL
these	NULL
kinases	NULL
,	NULL
the	NULL
activities	NULL
of	NULL
p70®®	NULL
kinase	NULL
(	NULL
60-62	NULL
)	NULL
and	NULL
PKC	NULL
(	NULL
63	NULL
)	NULL
are	NULL
affected	NULL
by	NULL
rapamycin	NULL
.	NULL

While	NULL
PKC	NULL
can	NULL
mediate	NULL
p70®°	NULL
kinase	NULL
phosphorylation	NULL
,	NULL
rapamycin	NULL
appears	NULL
to	NULL
act	NULL
downstream	NULL
of	NULL
PKC-mediated	NULL
p70°®°	NULL
kinase	NULL
activation	NULL
(	NULL
64	NULL
)	NULL
.	NULL

A	NULL
rapamycin-sensitive	NULL
kinase	NULL
in	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
pathway	NULL
to	NULL
activation	NULL
of	NULL
p70°®	NULL
kinase	NULL
is	NULL
FKBP12-rapamycin-associated	NULL
protein	NULL
(	NULL
FRAP	NULL
)	NULL
(	NULL
65	NULL
)	NULL
.	NULL

p70	NULL
kinase	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
stimulated	NULL
in	NULL
murine	NULL
T	NULL
cells	NULL
by	NULL
IL-2	NULL
(	NULL
66	NULL
)	NULL
and	NULL
inhibited	NULL
by	NULL
rapamycin	NULL
(	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
p70°®°	NULL
kinase	NULL
activity	NULL
can	NULL
be	NULL
inhibited	NULL
by	NULL
cAMP	NULL
acting	NULL
through	NULL
PKA	NULL
(	NULL
64	NULL
)	NULL
.	NULL

In	NULL
our	NULL
cells	NULL
,	NULL
active	NULL
PKA	NULL
levels	NULL
are	NULL
only	NULL
slightly	NULL
above	NULL
baseline	NULL
in	NULL
resting	NULL
and	NULL
IL-2-stimulated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
which	NULL
would	NULL
potentially	NULL
allow	NULL
for	NULL
normal	NULL
activity	NULL
of	NULL
p70®°	NULL
kinase	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
increase	NULL
in	NULL
CREB	NULL
kinase	NULL
activity	NULL
is	NULL
sensitive	NULL
to	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
but	NULL
the	NULL
kinase	NULL
is	NULL
not	NULL
affected	NULL
directly	NULL
by	NULL
rapamycin	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Previous	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
p70°®®	NULL
kinase	NULL
activation	NULL
is	NULL
rapamycin	NULL
sensitive	NULL
,	NULL
but	NULL
enzyme	NULL
activity	NULL
is	NULL
not	NULL
inhibited	NULL
directly	NULL
by	NULL
rapamycin	NULL
(	NULL
67	NULL
)	NULL
.	NULL

Thus	NULL
one	NULL
possibility	NULL
would	NULL
be	NULL
that	NULL
rapamycin	NULL
inhibits	NULL
FRAP	NULL
blocking	NULL
p70°®	NULL
kinase	NULL
activation	NULL
and	NULL
CREB	NULL
phosphorylation	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
the	NULL
existence	NULL
of	NULL
an	NULL
L2	NULL
variant	NULL
expressing	NULL
constitutively	NULL
phosphorylated	NULL
Ser'**	NULL
CREB	NULL
.	NULL

In	NULL
this	NULL
variant	NULL
,	NULL
constitutive	NULL
CREB	NULL
phosphorylation	NULL
alone	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
drive	NULL
PCNA	NULL
expression	NULL
and	NULL
cellular	NULL
proliferation	NULL
.	NULL

L2	NULL
cells	NULL
express	NULL
a	NULL
kinase	NULL
other	NULL
than	NULL
PKA	NULL
that	NULL
is	NULL
capable	NULL
of	NULL
phosphorylating	NULL
CREB	NULL
at	NULL
Ser	NULL
'	NULL
``	NULL
>	NULL
;	NULL
based	NULL
on	NULL
the	NULL
IL-2	NULL
inducibility	NULL
and	NULL
sensitivity	NULL
to	NULL
rapamycin	NULL
,	NULL
p70°°	NULL
kinase	NULL
is	NULL
a	NULL
candidate	NULL
kinase	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
CREB	NULL
phosphorylation	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
there	NULL
are	NULL
other	NULL
rapamycin-sensitive	NULL
events	NULL
that	NULL
are	NULL
the	NULL
rate	NULL
limiting	NULL
steps	NULL
in	NULL
IL-2-driven	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Sigal	NULL
,	NULL
N.	NULL
H.	NULL
,	NULL
and	NULL
F.	NULL
J.	NULL
Dumont	NULL
.	NULL

1992	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
FK-506	NULL
,	NULL
and	NULL
rapamycin	NULL
:	NULL
pharmacologic	NULL
probes	NULL
of	NULL
lymphocyte	NULL
signal	NULL
transduction	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10:519	NULL
.	NULL

2	NULL
.	NULL

Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
1991	NULL
.	NULL

Chemistry	NULL
and	NULL
biology	NULL
of	NULL
the	NULL
immunophilins	NULL
and	NULL
their	NULL
immunosuppressive	NULL
ligands	NULL
.	NULL

Science	NULL
251:283	NULL
.	NULL

3	NULL
.	NULL

Dumont	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
M.	NULL
J.	NULL
Staruch	NULL
,	NULL
S.	NULL
L.	NULL
Koprak	NULL
,	NULL
M.	NULL
R.	NULL
Melino	NULL
,	NULL
and	NULL
N.	NULL
H.	NULL
Sigal	NULL
.	NULL

1990	NULL
.	NULL

Distinct	NULL
mechanisms	NULL
of	NULL
suppression	NULL
of	NULL
murine	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
the	NULL
related	NULL
macrolides	NULL
FK-506	NULL
and	NULL
rapamycin	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

144:251	NULL
.	NULL

4	NULL
.	NULL

Jefferies	NULL
,	NULL
H.	NULL
B.	NULL
J.	NULL
,	NULL
C.	NULL
Reinhard	NULL
,	NULL
S.	NULL
C.	NULL
Kozma	NULL
,	NULL
and	NULL
G.	NULL
Thomas	NULL
.	NULL

1994	NULL
.	NULL

Rapamycin	NULL
selectively	NULL
represses	NULL
translation	NULL
of	NULL
the	NULL
``	NULL
polypyrimidine	NULL
tract	NULL
``	NULL
mRNA	NULL
family	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:4441	NULL
.	NULL

5	NULL
.	NULL

Feuerstein	NULL
,	NULL
N.	NULL
,	NULL
D.	NULL
Huang	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1995	NULL
.	NULL

Rapamycin	NULL
selectively	NULL
blocks	NULL
IL-2	NULL
induced	NULL
PCNA	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
lymphocytes	NULL
:	NULL
evidence	NULL
for	NULL
inhibition	NULL
of	NULL
CREB/ATF	NULL
binding	NULL
activities	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:9454	NULL
.	NULL

6	NULL
.	NULL

Prelich	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
K.	NULL
Tan	NULL
,	NULL
M.	NULL
Kostura	NULL
,	NULL
M.	NULL
B.	NULL
Mathews	NULL
,	NULL
A.	NULL
G.	NULL
So	NULL
,	NULL
K.	NULL
M.	NULL
Downey	NULL
,	NULL
and	NULL
B.	NULL
Stillman	NULL
.	NULL

1987	NULL
.	NULL

Functional	NULL
identity	NULL
of	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
and	NULL
a	NULL
DNA	NULL
polymerase	NULL
delta	NULL
auxiliary	NULL
protein	NULL
.	NULL

Nature	NULL
326:517	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36.	NULL
.	NULL

Bravo	NULL
,	NULL
R.	NULL
,	NULL
R.	NULL
Frank	NULL
,	NULL
P.	NULL
A.	NULL
Blundell	NULL
,	NULL
and	NULL
H.	NULL
Macdonald-Bravo	NULL
.	NULL

1987	NULL
.	NULL

Cyclin/	NULL
PCNA	NULL
is	NULL
the	NULL
auxiliary	NULL
protein	NULL
of	NULL
DNA	NULL
polymerase	NULL
delta	NULL
.	NULL

Nature	NULL
326:515.	NULL
.	NULL

Prelich	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
B.	NULL
Stillman	NULL
.	NULL

1988	NULL
.	NULL

Coordinated	NULL
leading	NULL
and	NULL
lagging	NULL
strand	NULL
syn-	NULL
thesis	NULL
during	NULL
SV40	NULL
DNA	NULL
replication	NULL
in	NULL
vitro	NULL
requires	NULL
PCNA	NULL
.	NULL

Cell	NULL
53:117.	NULL
.	NULL

Matthews	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
,	NULL
PCNA	NULL
,	NULL
a	NULL
cell	NULL
growth-regulated	NULL
DNA	NULL
replication	NULL
factor	NULL
.	NULL

In	NULL
Growth	NULL
Control	NULL
During	NULL
Cell	NULL
Aging	NULL
.	NULL

E.	NULL
Wang	NULL
and	NULL
H.	NULL
R.	NULL
Warner	NULL
,	NULL
eds	NULL
.	NULL

CRC	NULL
Press	NULL
,	NULL
Boca	NULL
Raton	NULL
,	NULL
Fla	NULL
,	NULL
p.	NULL
89	NULL
.	NULL

Krishna	NULL
,	NULL
T.	NULL
S.	NULL
R.	NULL
,	NULL
X.	NULL
P.	NULL
Kong	NULL
,	NULL
S.	NULL
Gary	NULL
,	NULL
P.	NULL
M.	NULL
Burgers	NULL
,	NULL
and	NULL
J.	NULL
Kuriyan	NULL
1994	NULL
;	NULL
crystal	NULL
structure	NULL
of	NULL
the	NULL
eukaryotic	NULL
DNA	NULL
polymerase	NULL
processivity	NULL
factor	NULL
PCNA	NULL
.	NULL

Cell	NULL
79:1233	NULL
.	NULL

Wong	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
M.	NULL
E.	NULL
Katz	NULL
,	NULL
K.	NULL
Ogata	NULL
,	NULL
E.	NULL
M.	NULL
Tan	NULL
,	NULL
and	NULL
S.	NULL
Cohen	NULL
.	NULL

1987	NULL
.	NULL

Inhibition	NULL
of	NULL
nuclear	NULL
DNA	NULL
synthesis	NULL
by	NULL
an	NULL
autoantibody	NULL
to	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
anti-gen/cyclin	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

110:443	NULL
.	NULL

Jakulski	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
K.	NULL
DeRiel	NULL
,	NULL
W.	NULL
E.	NULL
Mercer	NULL
,	NULL
B.	NULL
Calabretta	NULL
,	NULL
and	NULL
R.	NULL
Baserga	NULL
.	NULL

1988	NULL
.	NULL

Inhibition	NULL
of	NULL
cellular	NULL
proliferation	NULL
by	NULL
antisense	NULL
to	NULL
oligodeoxinucleotides	NULL
to	NULL
PCNA/cyclin	NULL
.	NULL

Science	NULL
240:1544	NULL
.	NULL

Shipman-Appasamy	NULL
,	NULL
P.	NULL
,	NULL
K.	NULL
Cohen	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1990	NULL
.	NULL

Interleukin	NULL
2-induced	NULL
expression	NULL
of	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
is	NULL
regulated	NULL
by	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:19180	NULL
.	NULL

Huang	NULL
,	NULL
D.	NULL
,	NULL
P.	NULL
Shipman-Appasamy	NULL
,	NULL
D.	NULL
J.	NULL
Orten	NULL
,	NULL
S.	NULL
H.	NULL
Hinrichs	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1994	NULL
.	NULL

Promoter	NULL
activity	NULL
of	NULL
the	NULL
proliferating-cell	NULL
nuclear	NULL
antigen	NULL
gene	NULL
is	NULL
associated	NULL
with	NULL
inducible	NULL
CRE-binding	NULL
proteins	NULL
in	NULL
interleukin	NULL
2-stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:4233	NULL
.	NULL

Huang	NULL
,	NULL
D.	NULL
Y.	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
essential	NULL
cis-element	NULL
near	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
for	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
proliferating	NULL
cell	NULL
nuclear	NULL
antigen	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:1218	NULL
.	NULL

Feuerstein	NULL
,	NULL
N.	NULL
,	NULL
D.	NULL
Huang	NULL
,	NULL
S.	NULL
H.	NULL
Hinrichs	NULL
,	NULL
D.	NULL
J.	NULL
Orten	NULL
,	NULL
N.	NULL
Aiyar	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
cAMP-responsive	NULL
enhancer	NULL
binding	NULL
proteins	NULL
during	NULL
cell	NULL
cycle	NULL
progression	NULL
in	NULL
T	NULL
lymphocytes	NULL
stimulated	NULL
by	NULL
IL-2	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:68	NULL
.	NULL

Meyer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1993	NULL
.	NULL

Cyclic	NULL
adenosine	NULL
3',5'-monophosphate	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
and	NULL
related	NULL
transcription	NULL
activating	NULL
deoxyribonucleic	NULL
acid	NULL
binding	NULL
proteins	NULL
.	NULL

Endocr	NULL
.	NULL

Rev	NULL
.	NULL

14:269	NULL
.	NULL

Hoeffler	NULL
,	NULL
J.	NULL
P.	NULL
1992	NULL
.	NULL

Structure/function	NULL
relationships	NULL
of	NULL
CREB/ATF	NULL
proteins	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

98:218	NULL
.	NULL

Lee	NULL
,	NULL
K.	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
N.	NULL
Masson	NULL
.	NULL

1993	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
by	NULL
CREB	NULL
and	NULL
its	NULL
relatives	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1174:221	NULL
.	NULL

Brindle	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
CREB	NULL
family	NULL
of	NULL
transcription	NULL
activators	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Gene	NULL
.	NULL

Dev	NULL
.	NULL

2:199	NULL
.	NULL

Gonzalez	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1989	NULL
.	NULL

Cyclic	NULL
AMP	NULL
stimulates	NULL
somatostatin	NULL
gene	NULL
transcription	NULL
by	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

Cell	NULL
59:675	NULL
.	NULL

Montiminy	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Bilezikjian	NULL
.	NULL

1987	NULL
.	NULL

Binding	NULL
of	NULL
a	NULL
nuclear	NULL
protein	NULL
to	NULL
the	NULL
cyclic-AMP	NULL
response	NULL
element	NULL
of	NULL
the	NULL
somatostatin	NULL
gene	NULL
.	NULL

Nature	NULL
328:175	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
G.	NULL
A.	NULL
Gonzalez	NULL
,	NULL
W.	NULL
H.	NULL
Biggs	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1988	NULL
.	NULL

Phosphorylation-induced	NULL
binding	NULL
and	NULL
transcriptional	NULL
efficacy	NULL
of	NULL
nuclear	NULL
factor	NULL
CREB	NULL
.	NULL

Nature	NULL
334:494	NULL
.	NULL

Hoeffler	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
T.	NULL
E.	NULL
Meyer	NULL
,	NULL
Y.	NULL
Yub	NULL
,	NULL
J.	NULL
L.	NULL
Jameson	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1988	NULL
.	NULL

Cyclic	NULL
AMP-responsive	NULL
DNA	NULL
binding	NULL
protein	NULL
:	NULL
structure	NULL
based	NULL
on	NULL
a	NULL
cloned	NULL
placental	NULL
cDNA	NULL
.	NULL

Science	NULL
242:1430	NULL
.	NULL

Ginty	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
A.	NULL
Bonni	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1994	NULL
.	NULL

Nerve	NULL
growth	NULL
factor	NULL
activates	NULL
a	NULL
Ras-dependent	NULL
protein	NULL
kinase	NULL
that	NULL
stimulates	NULL
c-fos	NULL
transcription	NULL
via	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
.	NULL

Cell	NULL
77:713	NULL
.	NULL

Sheng	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
A.	NULL
Thompson	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1991	NULL
.	NULL

CREB	NULL
:	NULL
A	NULL
Ca**-regulated	NULL
transcription	NULL
factor	NULL
phosphorylated	NULL
by	NULL
calmodulin-dependent	NULL
kinases	NULL
.	NULL

Science	NULL
252:1427	NULL
.	NULL

Bohm	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
Moellimann	NULL
,	NULL
E.	NULL
Cheng	NULL
,	NULL
M.	NULL
Alverez-Fronco	NULL
,	NULL
S.	NULL
Wagner	NULL
,	NULL
P.	NULL
Sassone-Corsi	NULL
,	NULL
and	NULL
R.	NULL
Halaban	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
of	NULL
p90'*	NULL
``	NULL
as	NULL
the	NULL
probable	NULL
CREB-ser	NULL
'	NULL
``	NULL
kinase	NULL
in	NULL
human	NULL
melanocytes	NULL
.	NULL

Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

6:291.	NULL
deGroot	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
L.	NULL
M.	NULL
Ballou	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1994	NULL
.	NULL

Positive	NULL
regulation	NULL
of	NULL
the	NULL
cAMP-responsive	NULL
activator	NULL
CREM	NULL
by	NULL
the	NULL
p70	NULL
S6	NULL
kinase	NULL
:	NULL
an	NULL
alternative	NULL
route	NULL
to	NULL
mitogen-induced	NULL
gene	NULL
expression	NULL
.	NULL

Cell	NULL
79:81	NULL
.	NULL

Xing	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
D.	NULL
Ginty	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1996	NULL
.	NULL

Coupling	NULL
of	NULL
the	NULL
RAS-MAPK	NULL
pathway	NULL
to	NULL
gene	NULL
activation	NULL
by	NULL
RSK2	NULL
,	NULL
a	NULL
growth	NULL
factor-regulated	NULL
CREB	NULL
kinase	NULL
.	NULL

Science	NULL
273:959	NULL
.	NULL

Nichols	NULL
,	NULL
M.	NULL
,	NULL
F.	NULL
Weih	NULL
,	NULL
W.	NULL
Schmid	NULL
,	NULL
C.	NULL
DeVack	NULL
,	NULL
E.	NULL
Kowenz-Leutz	NULL
,	NULL
B.	NULL
Luckow	NULL
,	NULL
M.	NULL
Boshart	NULL
,	NULL
and	NULL
G.	NULL
Schutz	NULL
.	NULL

1992	NULL
.	NULL

Phosphorylation	NULL
of	NULL
CREB	NULL
affects	NULL
its	NULL
binding	NULL
to	NULL
high	NULL
and	NULL
low	NULL
affinity	NULL
sites	NULL
:	NULL
implications	NULL
for	NULL
cAMP	NULL
induced	NULL
gene	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3337	NULL
.	NULL

Kramer	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
I.	NULL
Koornneef	NULL
,	NULL
S.	NULL
W.	NULL
delaat	NULL
,	NULL
and	NULL
A.	NULL
van	NULL
den	NULL
Eijnden-van	NULL
Raaij	NULL
.	NULL

1991	NULL
.	NULL

TGF-B1	NULL
induces	NULL
phosphorylation	NULL
of	NULL
the	NULL
cyclic	NULL
AMP	NULL
responsive	NULL
element	NULL
binding	NULL
protein	NULL
in	NULL
ML-CC164	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:1083	NULL
.	NULL

Dean	NULL
,	NULL
D.	NULL
C.	NULL
,	NULL
J.	NULL
J.	NULL
McQuillan	NULL
,	NULL
and	NULL
S.	NULL
Weintraub	NULL
.	NULL

1990	NULL
.	NULL

Serum	NULL
stimulation	NULL
of	NULL
fibronectin	NULL
gene	NULL
expression	NULL
appears	NULL
to	NULL
result	NULL
from	NULL
rapid	NULL
serum	NULL
induced	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
a	NULL
cAMP	NULL
response	NULL
element	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:3522	NULL
.	NULL

Englander	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
S.	NULL
G.	NULL
Widen	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Wilson	NULL
.	NULL

1991	NULL
.	NULL

Mammalian	NULL
B-poly-merase	NULL
promoter	NULL
:	NULL
phosphorylation	NULL
of	NULL
ATF/CRE	NULL
binding	NULL
protein	NULL
and	NULL
regulation	NULL
of	NULL
DNA	NULL
binding	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:3369	NULL
.	NULL

Roesler	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
G.	NULL
R.	NULL
Vandenbark	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Hanson	NULL
.	NULL

1988	NULL
.	NULL

Cyclic	NULL
AMP	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
eukaryotic	NULL
gene	NULL
transcription	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:9063	NULL
.	NULL

Tamir	NULL
,	NULL
A.	NULL
,	NULL
Y.	NULL
Granot	NULL
,	NULL
and	NULL
N.	NULL
Isakov	NULL
.	NULL

1996	NULL
.	NULL

Inhibition	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
by	NULL
cAMP	NULL
as	NULL
associated	NULL
with	NULL
down-regulation	NULL
of	NULL
two	NULL
parallel	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathways	NULL
,	NULL
the	NULL
extracellular	NULL
signal-related	NULL
kinase	NULL
and	NULL
c-Jun	NULL
N-ter-minal	NULL
kinase	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:1514	NULL
.	NULL

Glasebrook	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1980	NULL
.	NULL

Alloreactive	NULL
cloned	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

I.	NULL
Interactions	NULL
between	NULL
cloned	NULL
amplifier	NULL
and	NULL
cytolytic	NULL
T	NULL
cell	NULL
lines	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

151:876	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40.	NULL
.	NULL

Kemp	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
D.	NULL
J.	NULL
Graves	NULL
,	NULL
E.	NULL
Benjamini	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Krebs	NULL
.	NULL

1977	NULL
.	NULL

Role	NULL
of	NULL
multiple	NULL
42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

Sabath	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
D.	NULL
S.	NULL
Monos	NULL
,	NULL
S.	NULL
C.	NULL
Lee	NULL
,	NULL
C.	NULL
Deutsch	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1986	NULL
.	NULL

Cloned	NULL
T-cell	NULL
proliferation	NULL
and	NULL
synthesis	NULL
of	NULL
specific	NULL
proteins	NULL
are	NULL
inhibited	NULL
by	NULL
quinine	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:4739	NULL
.	NULL

Lee	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
D.	NULL
E.	NULL
Sabath	NULL
,	NULL
C.	NULL
Deutsch	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Prystowsky	NULL
.	NULL

1986	NULL
.	NULL

Increased	NULL
voltage-gated	NULL
potassium	NULL
conductance	NULL
during	NULL
interleukin	NULL
2-stimulated	NULL
proliferation	NULL
of	NULL
a	NULL
mouse	NULL
helper	NULL
T	NULL
lymphocyte	NULL
clone	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

102:1200	NULL
.	NULL

Schwartz	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
C.	NULL
S.	NULL
Rubin	NULL
.	NULL

1985	NULL
.	NULL

Identification	NULL
and	NULL
differential	NULL
expression	NULL
of	NULL
two	NULL
forms	NULL
of	NULL
regulatory	NULL
subunits	NULL
(	NULL
RI	NULL
)	NULL
of	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
II	NULL
in	NULL
friend	NULL
erythroleukemic	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

260:6296	NULL
.	NULL

Roskowski	NULL
,	NULL
R.	NULL
1983	NULL
.	NULL

Assays	NULL
of	NULL
protein	NULL
kinase	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

99:3.	NULL
basic	NULL
residues	NULL
in	NULL
determining	NULL
the	NULL
substrate	NULL
specificity	NULL
of	NULL
cyclic	NULL
AMP-dependent	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

252:4888	NULL
.	NULL

Glass	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
L.	NULL
J.	NULL
Lundquist	NULL
,	NULL
B.	NULL
M.	NULL
Katz	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Walsh	NULL
.	NULL

1989	NULL
.	NULL

Protein	NULL
kinase	NULL
inhibitor-	NULL
(	NULL
6-22	NULL
)	NULL
-amide	NULL
peptide	NULL
analogs	NULL
with	NULL
standard	NULL
and	NULL
nonstandard	NULL
amino	NULL
acid	NULL
substitutions	NULL
for	NULL
phenylalanine	NULL
10	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:14579	NULL
.	NULL

Prystowsky	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
K.	NULL
M.	NULL
Khan	NULL
,	NULL
and	NULL
W.	NULL
F.	NULL
Marovitz	NULL
.	NULL

1978	NULL
.	NULL

Detection	NULL
of	NULL
H2-b	NULL
and	NULL
Thy-1.2	NULL
surface	NULL
antigens	NULL
on	NULL
the	NULL
differentiating	NULL
murine	NULL
otocyst	NULL
using	NULL
Nomar-ski	NULL
optics	NULL
.	NULL

Differentiation	NULL
12:53	NULL
.	NULL

Barton	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Muthusamy	NULL
,	NULL
M.	NULL
Chanyangam	NULL
,	NULL
C.	NULL
Fischer	NULL
,	NULL
C.	NULL
Clendenin	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Leiden	NULL
.	NULL

1996	NULL
.	NULL

Defective	NULL
thymocyte	NULL
proliferation	NULL
and	NULL
IL-2	NULL
production	NULL
in	NULL
transgenic	NULL
mice	NULL
expressing	NULL
a	NULL
dominate-negative	NULL
form	NULL
of	NULL
CREB	NULL
.	NULL

Nature	NULL
379:81	NULL
.	NULL

Dash	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
K.	NULL
A.	NULL
Karl	NULL
,	NULL
M.	NULL
A.	NULL
Colicos	NULL
,	NULL
R.	NULL
Prywes	NULL
,	NULL
and	NULL
E.	NULL
R.	NULL
Kandel	NULL
.	NULL

1991.	NULL
cAMP	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
is	NULL
activated	NULL
by	NULL
Ca**	NULL
/calmodulin	NULL
as	NULL
well	NULL
as	NULL
cAMP	NULL
dependent	NULL
protein	NULL
kinase	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:5061	NULL
.	NULL

Sheng	NULL
,	NULL
M.	NULL
,	NULL
G.	NULL
McFadden	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1990	NULL
.	NULL

Membrane	NULL
depolarization	NULL
and	NULL
calcium	NULL
induce	NULL
c-fos	NULL
transcription	NULL
via	NULL
phosphorylation	NULL
of	NULL
transcription	NULL
factor	NULL
CREB	NULL
.	NULL

Neuron	NULL
4:571	NULL
.	NULL

Hseub	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Liang	NULL
,	NULL
S.	NULL
Ng	NULL
,	NULL
and	NULL
M.	NULL
Lai	NULL
.	NULL

1997	NULL
.	NULL

CD28-costimulation	NULL
activates	NULL
cyclic	NULL
AMP-responsive	NULL
element-binding	NULL
protein	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:85	NULL
.	NULL

Brindle	NULL
,	NULL
P.	NULL
,	NULL
T.	NULL
Nakajima	NULL
,	NULL
and	NULL
M.	NULL
Montminy	NULL
.	NULL

1995	NULL
.	NULL

Multiple	NULL
protein	NULL
kinase	NULL
A-regulated	NULL
events	NULL
are	NULL
required	NULL
for	NULL
transcriptional	NULL
induction	NULL
by	NULL
cAMP	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:10521	NULL
.	NULL

Feuerstein	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
L.	NULL
Lindsberg	NULL
,	NULL
L.	NULL
Tung	NULL
,	NULL
M.	NULL
L.	NULL
Francis	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Mond	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
prominent	NULL
85-kDa	NULL
cAMP-dependent	NULL
phosphoprotein	NULL
associated	NULL
with	NULL
late	NULL
G1	NULL
phase	NULL
in	NULL
mitogen-stimulated	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266:4746	NULL
.	NULL

Wang	NULL
,	NULL
T.	NULL
,	NULL
J.	NULL
R.	NULL
Sheppard	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Foker	NULL
.	NULL

1991	NULL
.	NULL

Rise	NULL
and	NULL
fall	NULL
of	NULL
cyclic	NULL
AMP	NULL
required	NULL
for	NULL
onset	NULL
of	NULL
lymphocyte	NULL
DNA	NULL
synthesis	NULL
.	NULL

Science	NULL
207:155	NULL
.	NULL

Nigg	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
H.	NULL
Hilz	NULL
,	NULL
H.	NULL
M.	NULL
Eppenberger	NULL
,	NULL
and	NULL
F.	NULL
Dutly	NULL
.	NULL

1991	NULL
.	NULL

Rapid	NULL
and	NULL
reversible	NULL
translocation	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
type	NULL
II	NULL
from	NULL
the	NULL
golgi	NULL
complex	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

4:2801	NULL
.	NULL

Kammer	NULL
,	NULL
G.	NULL
M.	NULL
1988	NULL
.	NULL

The	NULL
adenylate	NULL
cyclase-cAMP-protein	NULL
kinase	NULL
A	NULL
pathway	NULL
and	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
9:222	NULL
.	NULL

Hafner	NULL
,	NULL
S.	NULL
,	NULL
H.	NULL
S.	NULL
Adler	NULL
,	NULL
H.	NULL
Mischak	NULL
,	NULL
P.	NULL
Janosch	NULL
,	NULL
G.	NULL
Heidecker	NULL
,	NULL
A.	NULL
Wolfman	NULL
,	NULL
S.	NULL
Pippig	NULL
,	NULL
M.	NULL
Lohse	NULL
,	NULL
M.	NULL
Uceffing	NULL
,	NULL
and	NULL
W.	NULL
Kolch	NULL
.	NULL

1994	NULL
.	NULL

Mechanism	NULL
of	NULL
inhibition	NULL
of	NULL
Raf-1	NULL
by	NULL
protein	NULL
kinase	NULL
A.	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6696	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

665	NULL
Cheng	NULL
,	NULL
H.-C.	NULL
,	NULL
B.	NULL
E.	NULL
Kemp	NULL
,	NULL
R.	NULL
B.	NULL
Pearson	NULL
,	NULL
A.	NULL
J.	NULL
Smith	NULL
,	NULL
L.	NULL
Misconi	NULL
,	NULL
S.	NULL
M.	NULL
Van	NULL
Patten	NULL
,	NULL
and	NULL
D.	NULL
A.	NULL
Walsh	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
potent	NULL
synthetic	NULL
peptide	NULL
inhibitor	NULL
of	NULL
the	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

261:989	NULL
.	NULL

Montminy	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
Brindle	NULL
,	NULL
J.	NULL
Arias	NULL
,	NULL
K.	NULL
Ferreri	NULL
,	NULL
and	NULL
R.	NULL
Armstrong	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
somatostatin	NULL
gene	NULL
transcription	NULL
by	NULL
cyclic	NULL
andenosine	NULL
monophosphate	NULL
.	NULL

Metab	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

45:4	NULL
.	NULL

Colbran	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
P.	NULL
J.	NULL
Roach	NULL
,	NULL
C.	NULL
J.	NULL
Fiol	NULL
,	NULL
J.	NULL
E.	NULL
Dixon	NULL
,	NULL
O.	NULL
M.	NULL
Andrisiani	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Corbin	NULL
.	NULL

1992.	NULL
cAMP-dependent	NULL
protein	NULL
kinase	NULL
,	NULL
but	NULL
not	NULL
the	NULL
cGMP-depen-dent	NULL
enzyme	NULL
,	NULL
rapidly	NULL
phosphorylates	NULL
delta-CREB	NULL
,	NULL
and	NULL
a	NULL
synthetic	NULL
delta-CREB	NULL
peptide	NULL
.	NULL

Biochem	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

70:1277	NULL
.	NULL

Sheng	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
A.	NULL
Thompson	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Greenberg	NULL
.	NULL

1992	NULL
.	NULL

CREB	NULL
:	NULL
a	NULL
Ca**-regulated	NULL
transcription	NULL
factor	NULL
phosphorylated	NULL
by	NULL
calmodulin-dependent	NULL
kinases	NULL
.	NULL

Science	NULL
252:1427	NULL
.	NULL

Xie	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
mediates	NULL
activation	NULL
of	NULL
nuclear	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
in	NULL
B	NULL
lymphocytes	NULL
stimulated	NULL
through	NULL
surface	NULL
Ig	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

1717.	NULL
de	NULL
Groot	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
J.	NULL
den	NULL
Hertog	NULL
,	NULL
J.	NULL
Vandenheede	NULL
,	NULL
J.	NULL
Goris	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1993	NULL
.	NULL

Multiple	NULL
and	NULL
cooperative	NULL
phosphorylation	NULL
events	NULL
regulate	NULL
the	NULL
CREM	NULL
activator	NULL
function	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3903	NULL
.	NULL

Calvo	NULL
,	NULL
V.	NULL
,	NULL
C.	NULL
M.	NULL
Crews	NULL
,	NULL
T.	NULL
A.	NULL
Vik	NULL
,	NULL
and	NULL
B.	NULL
E.	NULL
Bieter	NULL
.	NULL

1992	NULL
.	NULL

Interleukin	NULL
2	NULL
stimulation	NULL
of	NULL
p70	NULL
S6	NULL
kinase	NULL
activity	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
immunosuppressant	NULL
rapamycin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7571	NULL
.	NULL

Kuo	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
J.	NULL
Chung	NULL
,	NULL
D.	NULL
F.	NULL
Fiorentino	NULL
,	NULL
W.	NULL
M.	NULL
Flanagan	NULL
,	NULL
J.	NULL
Blenis	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1992	NULL
.	NULL

Rapamycin	NULL
selectively	NULL
inhibits	NULL
interleukin-2	NULL
activation	NULL
of	NULL
p70	NULL
S6	NULL
kinase	NULL
.	NULL

Nature	NULL
358:70.	NULL
de	NULL
Groot	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
L.	NULL
M.	NULL
BNallou	NULL
,	NULL
and	NULL
P.	NULL
Sassone-Corsi	NULL
.	NULL

1994	NULL
.	NULL

Positive	NULL
regulation	NULL
of	NULL
the	NULL
cAMP	NULL
responsive	NULL
activator	NULL
CREM	NULL
by	NULL
the	NULL
p70	NULL
S6	NULL
kinase	NULL
:	NULL
an	NULL
alternative	NULL
route	NULL
to	NULL
mitogen	NULL
induced	NULL
gene	NULL
expression	NULL
.	NULL

Cell	NULL
79:81	NULL
.	NULL

Kimbal	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
R.	NULL
K.	NULL
Kerman	NULL
,	NULL
C.	NULL
T.	NULL
VanBuren	NULL
,	NULL
R.	NULL
M.	NULL
Lewis	NULL
,	NULL
S.	NULL
Katz	NULL
,	NULL
and	NULL
B.	NULL
D.	NULL
Kahan	NULL
.	NULL

1993	NULL
.	NULL

Cyclosporine	NULL
and	NULL
rapamycin	NULL
affect	NULL
protein	NULL
kinase	NULL
C	NULL
induction	NULL
of	NULL
the	NULL
intracellular	NULL
activation	NULL
signal	NULL
,	NULL
activator	NULL
of	NULL
DNA	NULL
replication	NULL
.	NULL

Transplantation	NULL
55:1128	NULL
.	NULL

Monfar	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
P.	NULL
Lemon	NULL
,	NULL
T.	NULL
C.	NULL
Grammer	NULL
,	NULL
L.	NULL
Cheatham	NULL
,	NULL
J.	NULL
Chung	NULL
,	NULL
C.	NULL
J.	NULL
Vlahos	NULL
,	NULL
and	NULL
J.	NULL
Blenis	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
of	NULL
pp70/85	NULL
kinases	NULL
in	NULL
interleukin-2-responsive	NULL
lymphoid	NULL
cells	NULL
is	NULL
mediated	NULL
by	NULL
phosphatidylinositol	NULL
3-kinase	NULL
and	NULL
inhibited	NULL
by	NULL
cyclic	NULL
AMP	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:326	NULL
.	NULL

Brown	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
P.	NULL
A.	NULL
Beal	NULL
,	NULL
C.	NULL
T.	NULL
Keith	NULL
,	NULL
J.	NULL
Chen	NULL
,	NULL
T.	NULL
B.	NULL
Shin	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
Schreiber	NULL
.	NULL

1995	NULL
.	NULL

Control	NULL
of	NULL
p70	NULL
S6	NULL
kinase	NULL
by	NULL
kinase	NULL
activity	NULL
of	NULL
FRAP	NULL
in	NULL
vivo	NULL
.	NULL

Nature	NULL
377:441	NULL
.	NULL

Evans	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
and	NULL
W.	NULL
L.	NULL
Farrar	NULL
.	NULL

1987	NULL
.	NULL

Interleukin	NULL
2	NULL
and	NULL
diacylglycerol	NULL
stimulate	NULL
phosphorylation	NULL
of	NULL
40	NULL
S	NULL
ribosomal	NULL
S6	NULL
kinase	NULL
activation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262:4624	NULL
.	NULL

Chung	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
J.	NULL
Kuo	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
J.	NULL
Blenis	NULL
.	NULL

1992	NULL
.	NULL

Rapamycin-FKBP	NULL
specifically	NULL
blocks	NULL
growth-dependent	NULL
activation	NULL
of	NULL
and	NULL
signaling	NULL
by	NULL
the	NULL
70	NULL
kd	NULL
S6	NULL
protein	NULL
kinases	NULL
.	NULL

Cell	NULL
69:1227	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
1san8	NULL
4g	NULL
810	NULL
wor	NULL
;	NULL

